First phase insulin response in children with islet autoantibodies : results from the Finnish Type 1 Diabetes Prediction and Prevention study by Koskinen, Maarit
M
aarit Koskinen
D
 1450
A
N
N
A
LES U
N
IV
ERSITATIS TU
RK
U
EN
SIS
ISBN 978-951-29-7836-6 (PRINT)
ISBN 978-951-29-7837-3 (PDF)
ISSN 0355-9483 (Painettu/Print)
ISSN 2343-3213 (Sähköinen/Online)
Pa
in
os
al
am
a 
O
y, 
Tu
rk
u,
 F
in
la
nd
 2
01
9
TURUN YLIOPISTON JULKAISUJA –  ANNALES UNIVERSITATIS TURKUENSIS
SARJA - SER. D OSA  - TOM. 1450  | MEDICA - ODONTOLOGICA | TURKU 2019
FIRST PHASE 
INSULIN RESPONSE IN 
CHILDREN WITH ISLET 
AUTOANTIBODIES
Results from the Finnish Type 1 Diabetes 
Prediction and Prevention study
Maarit Koskinen
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST PHASE  
INSULIN RESPONSE IN 
CHILDREN WITH ISLET 
AUTOANTIBODIES 
Results from the Finnish Type 1 Diabetes 
Prediction and Prevention study 
 
 
Maarit Koskinen 
TURUN YLIOPISTON JULKAISUJA –  ANNALES UNIVERSITATIS TURKUENSIS 
SARJA - SER. D - TOM. 1450 | MEDICA-ODONTOLOGIA TURKU 2019 
University of Turku 
 
Faculty of Medicine 
Department of Paediatrics 
Doctoral programme in Clinical Research 
 
Supervised by  
Professor Jorma Toppari 
Institute of Biomedicine 
University of Turku 
Department of Paediatrics  
Turku University Hospital  
Professor Riitta Veijola 
Department of Pediatrics  
University of Oulu  
Oulu University Hospital 
Reviewed by 
 
Professor Karl-Heinz Herzig 
Department of Physiology  
University of Oulu 
Oulu University Hospital  
Docent Terhi Tapiainen  
Departmert of Pediatrics and Adolescence  
University of Oulu 
Oulu University Hospital 
Opponent 
 
Associate professor Tiinamaija Tuomi 
Helsinki University Hospital 
Abdominal Center, Department of Endocrinology 
University of Helsinki 
Insititute for Molecular Medicine Finland FIMM 
Folkhälsan Research Center, Helsinki 
Professor, Lund University Diabetes Center, Sweden 
 
The originality of this publication has been checked in accordance with the University 
of Turku quality assurance system using the Turnitin OriginalityCheck service. 
 
 
ISBN 978-951-29-7836-6 (PRINT) 
ISBN 978-951-29-7837-3 (PDF) 
ISSN 0355-9483 (Painettu/Print) 
ISSN 2343-3213 (Sähköinen/Online) 
Painosalama, Turku, Finland 2019 
 3 
UNIVERSITY OF TURKU  
Faculty of Medicine 
Department of Paediatrics 
MAARIT KOSKINEN: First phase insulin response in children with islet 
autoantibodies. Results from the Finnish Type 1 Diabetes Prediction and 
Prevention study  
Doctoral Dissertation, 117 pp. 
Doctoral Programme in Clinical Research   
November 2019 
ABSTRACT 
Type 1 diabetes results from the deficiency of insulin secretion from the pancreatic 
beta cells. The preclinical period of type 1 diabetes is characterized by the 
appearance of islet autoantibodies in the peripheral blood and appearance of two or 
more autoantibodies is highly predictive of clinical type 1 diabetes. The aim of this 
thesis was to investigate beta cell function in children from the Finnish Type 1 
Diabetes Prediction and Prevention (DIPP) study. The DIPP study screens newborns 
for class II HLA associated risk for type 1 diabetes and follows children regularly. 
One or more intravenous glucose tolerance tests (IVGTTs) were performed for 
children who had developed islet autoantibodies.  
In progressors a declined first phase insulin response (FPIR) to glucose was 
observed 4-6 years prior to diagnosis as compared to non-progressors. Furthermore, 
in the age dependent comparison children progressing to T1D had lower FPIR than 
non-progressors throughout the whole childhood and this difference increased over 
time. When the association between FPIR and class II HLA was studied, it was 
observed that the class II HLA association was secondary to the appearance of 
autoantibodies. Declining pattern of FPIR was associated with multiple 
autoantibodies irrespective of class II HLA risk. Genetic variants outside the class II 
HLA region were, however, associated with the longitudinal pattern of FPIR. 
This study showed that in children that progress to clinical T1D the beta cell 
secretory capacity is reduced years before the onset of the disease.  
KEYWORDS: type 1 diabetes, beta cell function, insulin, glucose metabolism, 
HLA, autoantibodies, IVGTT, preclinical 
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TIIVISTELMÄ 
Tyypin 1 diabetes johtuu haiman betasolujen insuliinin erityksen puutteesta. 
Prekliinisenä aikana ennen tyypin 1 diabetesta perifeeriseen verenkiertoon ilmaantuu 
autovasta-aineita haiman saarekesoluja vastaan. Tyypin 1 diabeteksen riski on 
selkeästi lisääntynyt, kun lapselle on ilmaantunut kaksi tai useampi erilaista 
autovasta-ainetta. Tämän väitöskirjan tarkoituksena oli tutkia betasolujen toimintaa 
suomalaisen DIPP-tutkimuksen lapsilla. Yksi tai useampi suonensisäinen 
sokerirasituskoe tehtiin lapsille, joille oli ilmaantunut autovasta-aineita. 
Ensimmäisessä työssä tutkittiin glukoosin aineenvaihduntaa terveillä ja tyypin 1 
diabetekseen sairastuvilla lapsilla. Sairastuvilla ensivaiheen insuliinivaste oli 
laskenut jo 4-6 vuotta ennen diagnoosia. Lisäksi iän mukaisessa vertailussa 
sairastuvilla lapsilla ensivaiheen insuliinivaste pysyi matalana koko lapsuuden ja ero 
ryhmien välillä kasvoi iän myötä. 
Kun tutkittiin luokan II HLA alueen ja ensivaiheen insuliinivasteen välisiä 
yhteyksiä, havaittiin, että yhteys johtui autovasta-aineista. Ajan myötä heikkenevä 
insuliinivaste oli yhteydessä kahden  tai useamman autovasta-aineen esiintymiseen 
riippumatta luokan II HLA genotyyppiin liittyvästä riskistä. Muiden luokan II HLA 
alueen ulkopuolisten geneettisten varianttien ja insuliinivasteen välillä löytyi 
kuitenkin yhteyksiä.  
Tämä tutkimus osoitti, että lapsilla, jotka sairastuvat tyypin 1 diabetekseen 
betasolujen kyky erittää insuliinia on vähentynyt jo vuosia ennen kliinistä 
diagnoosia.  
AVAINSANAT: tyypin 1 diabetes, betasolujen toiminta, insuliini, glukoosi-
metabolia, HLA, autovasta-aineet, IVGTT, prekliininen
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1 Introduction 
Type 1 Diabetes (T1D), one of the most common chronic diseases in childhood and 
adolescence, has the world’s highest incidence in Finland. Type 1 diabetes results 
from a deficiency in  insulin secretion by the pancreatic beta cells. The preclinical 
period preceding the clinical onset of T1D is  characterized by the appearance of islet 
autoantibodies in the peripheral blood.  
In this thesis beta cell function was studied in children  who  participated in the 
Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study. The DIPP study 
screens for a class II HLA associated risk for type 1 diabetes. Children with specific 
genotypes are invited to follow-up and repeatedly tested for signs of islet 
autoimmunity. Intravenous glucose tolerance tests (IVGTTs), a method to assess the 
beta cell function, were performed to DIPP children with islet autoantibodies.   
The incidence of T1D has significantly increased in different populations. Many 
hypotheses have tried to explain this phenomenon. It has been suggested that beta 
cells are overloaded. We hypothesized that changes in beta cell function could 
contribute to the development of islet autoimmunity and T1D. In this study, we 
aimed to investigate beta cell function in children who develop T1D and those who 
remain healthy.  
  11 
2 Review of literature 
2.1 History of type 1 diabetes 
The etiology of type 1 diabetes (T1D) is still unknown, but the typical symptoms of 
T1D were identified as early as in the BC era. The disease which  was at the time 
characterized as “passing too much urine” was treated with nutritional management 
such as wheat grains, grapes, berries and sweet beer. The field of metabolism and 
diabetes was intensely investigated in the 19th century. Work done by a French 
physiologist Claude Bernard (1813-1878) included the demonstration that blood 
glucose levels are regulated by the absorption of dietary carbohydrates.  His concept 
of milieu interieur, i.e., internal environment, was later refined as homeostasis by  
American physiologist Walter Cannon (1871–1945).  
The islets of Langerhans, containing the endocrine, hormone-producing, cells of 
the pancreas, were named after the discoverer Paul Langerhans (1847-1888). Still an 
undergraduate, Langerhans was the first to describe them in 1869 (Langerhans, 
1869). In his dissertation he described highly innervated pale-stained areas with a 
rich vascular network throughout the pancreas but did not suggest any function to 
them. It was later, in 1893 that these cell clusters were named after him by a French 
pathologist and histologist Edouard Laguesse (1861-1927) (Laguesse, 1893). 
Years later, in 1889, Oscar Minkowski (1858-1931) and Joseph von Mering 
(1849-1908) discovered that it was the pancreas that was important for glucose 
homeostasis: they had removed dogs’ pancreases, and this resulted in fatal diabetes 
(von Mering J, Minkowski O., 1890). This finding was the first experimental 
evidence that diabetes could be of pancreatic origin. 
French physician Etienne Lancereaux (1829-1910) had suspected diabetes to be 
of pancreatic origin and had already made a distinction between two primary forms 
of diabetes in 1877. Later, in 1936, Harold Himsworth (1905-1993) tested these 
subtypes: both oral glucose and intravenous insulin were given to patients with 
diabetes. Two patterns were observed, one with immediate suppression of 
hyperglycemia after insulin administration (‘insulin-sensitive’) and other where the 
suppression was attenuated (‘insulin-insensitive’/’insulin-resistant’) (Himsworth, 
1936). The autoantibodies associated with T1D were discovered in 1974 (Bottazzo 
Maarit Koskinen 
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et al., 1974; MacCuish et al., 1974), and the first reports of genetic associations were 
published in the 1970’s (Nerup et al., 1974; Singal & Blajchman, 1973).  
2.1.1 The discovery of insulin  
On October 30th, 1920, a 28-year old surgeon named Frederick Banting (1891-1941) 
was preparing a lecture for medical students in the University of Western Ontario 
when his attention was caught by article “The relation of the islets of Langerhans to 
diabetes with special reference to cases of pancreatic lithiasis” (Barron, 1920). The 
following night, unable to sleep, he came across the idea of ligating pancreatic ducts 
in dogs and collecting the pancreatic extract. He was advised to present his idea to 
professor John James Rickard McLeod (1876-1935) at the Department of Physiology 
in the University of Toronto, and, after two meetings, Banting had convinced him 
enough. Professor McLeod provided a working space as well as medical student 
Charles Best (1899-1978) to help him with the investigation. 
The collaboration between Banting and Best was successful. They actively tried 
different methods and proceeded quickly with their work. Although the initial idea 
of duct ligation was eventually discarded, they had learned how to collect pancreatic 
extracts. There were problems with purity of the extract, so a visiting biochemist 
James Collip (1892-1965) later collaborated with them. Collip was able to remove 
impurities and prepare clean insulin.  
On January 1922, insulin, which was later completely purified, was given to 
Leonard Thompson, a 14-year-old boy with severe diabetic ketoacidosis. 
Thompson’s previous treatment had been dietetic regulation and he had been in the 
hospital for over a month. The treatment with insulin was soon proven to be a 
success. A preliminary report under the title “Pancreatic Extracts in the Treatment 
of Diabetes Mellitus” was published in March with emphasis on the first patient 
(Banting et al., 1922). The discovery and use of insulin meant that people with type 
1 diabetes could survive. Banting and MacLeod were awarded a Nobel Prize in 1923, 
and they shared the prize with Best and Collip, respectively. 
2.2 Pathophysiology of type 1 diabetes  
Glucose homeostasis is the process that keeps blood glucose at a steady-state level, 
maintaining equilibrium despite ongoing fluctuations. The word homeostasis comes 
from Greek and essentially means ’staying the same’. 
Insulin is needed for glucose to enter the cells. In most of the cells in the body, 
glucose is the main source of energy through the generation of ATP in the 
tricarboxylic acid cycle in mitochondria. Due to the deficiency of insulin glucose 
cannot enter the cell, and this leads to a derangement in the glucose homeostasis. 
Review of literature 
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Physiologically, insulin is secreted from the pancreas into the portal vein in a 
pulsatile fashion (Hellman et al, 2009; Song et al., 2000). In T1D, the normally 
occurring insulin pulsatility is absent and the instant feedback loop between the liver 
and pancreatic beta cells is disturbed. The insulin response to glucose, measured as 
the first phase insulin response (FPIR) is obliterated. 
2.3 Symptoms and diagnosis of type 1 diabetes 
Typical symptoms of T1D are polyuria, polydipsia and unexplained weight loss 
(Table 1). Diabetes is diagnosed according to the WHO and ADA criteria (Alberti 
& Zimmet, 1998; American Diabetes Association, 2018), and ISPAD 
recommendations (Craig et al., 2014). When  the glucose level in  circulation exceeds 
the renal glucose threshold, the resultant osmotic diuresis causes symptoms of thirst 
and polyuria. Insulin-sensitive target organs, such as muscle and adipose tissues  do 
not receive adequate glucose without insulin. In the absence of glucose, energy is 
produced from free fatty acids and amino acids. Protein and fat breakdown causes 
weight loss and ketone accumulation causing eventually life-threatening 
ketoacidosis.  
Table 1.  The diagnostic criteria of type 1 diabetes.  
Fasting glucose ≥ 7.0 mmol/l, or 
Plasma glucose ≥ 11.1 mmol/l at 2 hours during OGTT, or 
Classic symptoms of diabetes (polyuria, polydipsia, enuresis, unexplained weight loss) with a 
random plasma glucose of ≥11.1 mmol/l 
 
2.4 Epidemiology of type 1 diabetes  
Finland has the world’s highest incidence of T1D. In 2017 the annual incidence rate 
of T1D was 62/100000/year in children and adolescents under 15 years of age 
(www.diabetesatlas.org). Other countries with a high incidence of T1D in children 
under 15 are Sweden and Kuwait (both 42/100 000/year). 
During World War II there was a registry of patients in Finland who received 
insulin or diet supplements. Although this registry was incomplete it reported 250 
individuals under the age of 20 who had diabetes (population at the time was 3.6 
million) (Vartiainen, 1944).  
In 1953 (Somersalo, 1954) a more detailed report was made when a 
questionnaire was sent to all 2188 Finnish physicians. There were 663 children born 
since 1939 that developed diabetes under the age of 15 and 169 individuals had died 
Maarit Koskinen 
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with a diagnosis of diabetes. The incidence of new cases in 1953 was estimated to 
be 12.5/100,000/year (Somersalo, 1954). Since then, the overall incidence has 
increased and started to plateau in 2011 (Table 2). 
Table 2.  The incidence of type 1 diabetes in children under 15 years in Finland from 1965 to 
2011. Incidence is shown /100,000/year (95% confidence interval).  
Time   Overall incidence Boys Girls Reference 
1965-1980* 28 (27-28) 29 (28-30) 26 (25-27) (Tuomilehto et al., 1991)  
1980-1984* 34 (33-36) 37 (34-39) 32 (30-34) (Harjutsalo et al., 2008)  
1990-1994* 39 (38-41) 40(38-43) 39 (36-41) (Harjutsalo et al., 2008) 
2006 65 (60-70) 69 (62-77) 60 (53-68) (Harjutsalo et al., 2013)  
2011 64 (60-70) 76 (68-85) 52 (46-60) (Harjutsalo et al., 2013)  
*the mean annual incidence per 100,000 per year (95% CI) 
2.5 Prediction of type 1 diabetes 
Much of the data currently known about the pathogenesis process of T1D comes 
from longitudinal studies that have followed selected population based on their 
estimated genetic risk, family history or location (Table 3). 
Besides revealing several risk factors associated with type 1 diabetes, 
prospective studies have served as a platform for prevention trials and resulted in 
better metabolic control at diagnosis reducing the frequency of diabetic ketoacidosis 
(Hekkala, et al, 2017; Lundgren et al., 2014). 
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Table 3.  Some of the prospective studies that have followed selected population and the 
development of type 1 diabetes.  
Study (recruitment 
began/ recruitment 
period) 
Country Population Subjects with 
T1D after 
follow-up 
(total) 
Reference 
Cardiovascular Study in 
Young Finns (1980) 
Finland  General 
population 
18 (3475)  (Knip et al., 
2010)  
Childhood Diabetes in 
Finland DiMe (1986-
1989)  
Finland Siblings  of 
children with T1D  
47 (701) (Mrena et al., 
2006) 
BABYDIAB-BABYDIET 
(1989-2006) 
Germany  Relatives of 
patients with T1D 
115 (2441) (Hoffmann et 
al., 2019) 
Australian Babydiab 
(1993) 
Australia Relatives of 
patients with T1D  
12 (548) (Couper et al., 
2009) 
The Diabetes 
Autoimmunity Study in 
the Young DAISY 
(1993-2004) 
USA Class II HLA risk 
genotypes and 
relatives of 
patients with T1D  
94 (2547) (Frohnert et al., 
2018) 
The Finnish Type 1 
Diabetes Prediction and 
Prevention study DIPP 
(1994-ongoing) 
Finland Class II HLA risk 
genotypes  
388 (15253) (Bauer et al., 
2019) 
All Babies in Southeast 
Sweden ABIS (1997-
1999) 
Sweden General 
population 
116 (17055) (Ludvigsson et 
al., 2017) 
Diabetes Prediction in 
Skåne DiPis (2000-
2004) 
Sweden Class II HLA risk 
genotypes 
51 (4340) (Lundgren et 
al., 2019)  
The Environmental 
Determinants of the 
Diabetes in the Young 
TEDDY (2004-ongoing) 
USA, Finland, 
Sweden, 
Germany 
Class II HLA risk 
genotypes 
310 (8676) (Rewers et al., 
2018) 
TrialNet Pathway to 
Prevention (2004-
ongoing) 
USA, Finland, 
Australia, UK, 
NZ, Canada, 
Sweden, 
Germany, Italy 
Relatives of 
patients with T1D 
549 (4063) (Evans-Molina 
et al., 2018) 
2.5.1 Environmental risk factors of type 1 diabetes  
Several hypotheses have been proposed to explain the observed increase in T1D 
(Dahlquist et al., 2006; Rook et al., 2012; Wilkin et al., 2001) The frequencies of 
class II HLA genotypes in patients with T1D has changed over time, which suggests 
stronger environmental role in the disease process (Hermann et al., 2003).  
Maarit Koskinen 
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Many prenatal risk factors, such as maternal age can affect the risk of T1D. The 
maternal age over 35 increased the risk of T1D in Swedish children under 15 years 
(OR 1.36, 95% confidence interval [CI] 1.15-1.59) (Dahlquist & Källén, 1992). 
Caesarean section (CS) was associated with increased risk of T1D (OR 1.32, 95%CI 
1.14-1.52) (Dahlquist & Källén, 1992). This finding was not confirmed in a large 
Norwegian population-based study (Stene et al., 2003) Later study found an initial 
association between CS and the increased risk of T1D, but the association was lost 
after adjustments (OR 1.34, 95% CI 1.01-1.78) (Stene et al., 2004). Certain 
genotypes may modify the risk conferred by the delivery mode (Bonifacio et al., 
2011; Stene et al., 2011). 
Growth patterns in children have also been linked to the risk of T1D. Increased 
weight gain in infancy has been reported to be associated with an increased risk of 
T1D (Baum et al., 1975; Couper et al., 2009; Hyppönen et al., 1999). In the DiMe 
study where the index children with T1D were retrospectively investigated there 
were no significant differences in birth weight between children with T1D or their 
date and sex matched controls (Hyppönen et al., 1999). In young DiMe children the 
prevalence of obesity has been associated with an increased risk of T1D (OR 2.37, 
95% CI 1.07-5.26 in 4-year-old children) (Hyppönen et al., 2000). In the TEDDY 
study the prevalence of obesity has been reported as being linked to specific HLA 
genotypes in 2-4-year-old children (Yang et al., 2014). There was an association 
between weight at 1 year of age and the development of islet autoimmunity in the 
TEDDY study (HR 1.16, 95% CI 1.06-1.27) (Elding Larsson et al., 2016). In the 
DiPis study there was no difference between weight gain in subjects with T1D and 
the controls; children with T1D were taller at birth compared to their non-HLA 
matched controls, but not when compared to HLA matched controls (Larsson et al., 
2008). The relative height increase has been linked to an increased risk of T1D 
(Dahlquist et al., 1991; Hyppönen et al., 2000). In 0-4-year-old children an increased 
height over 0.1 standard deviation (SD) has been linked to an increased risk of T1D 
(OR 3.09, 95% CI 1.21-7.94) (Dahlquist et al., 1991). In the DAISY study, faster 
growth (in height) (1 SD difference) was associated with the development of islet 
autoimmunity (HR 1.63, 95% CI 1.31-2.05) and T1D development (adjusted HR 
3.34, 95% CI 1.73-6.42). Weight gain velocity (1 SD difference) did not display the 
same association (HR 0.88, 95% CI 0.69-1.11; HR 1.01, 95% CI 0.58-1.77, 
respectively) (Lamb et al., 2009). 
When children in the age range of 0-15 years with recent onset of T1D were 
investigated, an association between enteroviruses (EV) and an increased risk of 
T1D has been observed (OR 7.21, 95% CI 3.27-15.89) (Nairn et al., 1999). In another 
study EV RNA was found in 20 % (10/50) of subjects with preclinical T1D, in 36 % 
(17/47) of newly diagnosed T1D patients and in 4% (2/50) of control children, 
showing increased risk of T1D in patients with EV RNA (OR 6.0, 95% CI 1.2-29 in 
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preclinical T1D and OR 13.6, 95% CI 2.9-63 in newly diagnosed) (Moya-Suri et al., 
2005). In young DIPP study children, there was a temporal aspect to EV infection 
during the 6-month period preceding the first detection of islet autoantibodies 
compared to children without islet autoantibodies (evidence of EV infection by 
serological testing OR 3.7, 95% CI 1.2-11.4) (Lönnrot et al., 2000). The development 
of autoimmunity was increased in those who had an EV infection before the age of 
12 months and were exposed to cow’s milk before the age of 3 months (Lempainen 
et al., 2012). More specifically, it was observed in the DIPP study that EV RNA was 
more often found in serum samples before the appearance of islet autoantibodies 
from children who  progressed to T1D than in samples from non-progressors (OR 
7.7 (95% CI 1.9-31.5) (Oikarinen et al., 2011). A peak of EV RNA was also observed 
in stools before appearance of islet autoantibodies (Honkanen et al., 2017). In more 
detail, coxsackie B1 infections were associated with the appearance of IAA only as 
the first islet autoantibody (Sioofy-Khojine et al., 2018). 
Some associations between T1D risk and vaccinations have been found (Blom 
et al., 1991; Dahlquist et al., 1991; Elding Larsson et al., 2018). The lack of measles 
vaccination was associated with an increased risk of T1D in the age group of 5-9 
years (OR 3.33, 95% CI 1.28-8.65) (Dahlquist et al., 1991). In Finnish children from 
the TEDDY study the influenza vaccination was associated with decreased risk of 
autoimmunity and T1D (HR 0.47, 95% CI 0.29-0.75; HR 0.38, 95% CI 0.20-0.72, 
respectively)(Elding Larsson et al., 2018). Interestingly, rotavirus vaccinations were 
introduced in USA in 2006 and Australia in 2007, after which there was a decrease 
in the incidence of T1D in children aged 0-4 years in both countries (Perrett et al., 
2019; Rogers et al., 2019). In the Australian Babydiab study, rotavirus infections and 
the development of islet autoimmunity have been reported as temporally associated 
in high risk children (Honeyman et al., 2000). 
The duration of breastfeeding did not affect the risk of T1D in the DAISY study 
even if the child was breastfed at the time of introduction of solid foods (HR 0.97, 
95% CI 0.92-1.01; HR 0.70, 95% CI 0.38-1.28, respectively). However, if the child 
was breastfed at the time of introduction of wheat/barley, protection against T1D 
was observed (adjusted HR 0.47, 95% CI 0.26-0.86) (Frederiksen et al., 2013). Late 
introduction of gluten to the diet was linked to an increased risk of islet 
autoimmunity (HR 1.57, 95% CI 1.07-2.31) and early introduction was modestly 
associated with a lower risk (HR 0.68; 95% CI 0.47-0.99) when compared to the 
introduction between 4 and 9 months (Uusitalo et al., 2018). Cow’s milk has been 
associated with the risk of T1D, but results are contradictory. Early introduction of 
formula (before the age of 3 months vs. after 3 months) was associated with an 
increased risk of T1D in a retrospective study (adjusted OR 1.53, 95% CI 1.1-2.2) 
(Dahlquist et al., 1990). The TRIGR study tested the use of casein hydrolysate 
formula during the first 8 months of life but there was no effect on the development 
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of autoimmunity or T1D (Writing Group for the TRIGR Study Group et al., 2018). 
Genetic background may influence how the exposure to cow’s milk affects T1D risk 
(Lempainen et al., 2009).  
The intake of sugars and carbohydrates has been associated with the risk of T1D. 
In the DAISY study, sugar intake was linked to an increased progression rate to 
diabetes in children with multiple autoantibodies (HR 1.75, 95% CI 1.07-2.85) 
(Lamb et al., 2015). Compared to the lowest quartile, the carbohydrate intake of 25-
75th percentiles was not associated with an increased risk of T1D but at over the 75th 
centile positively carried this association (OR 1.44, 95% CI 0.98-2.12; OR 4.67, 95% 
CI 3.02-7.23, respectively) (Dahlquist et al., 1991). 
Vitamin D supplementation has been thought to offer protection against the 
development of T1D, and some meta-analyses have concluded that vitamin D 
supplementation may reduce the risk of T1D (Dong et al., 2013; Zipitis & Akobeng, 
2008). In the DIPP study there was no association between serum 25-
hydroxyvitamin D levels and the development of T1D (Mäkinen et al., 2016); 
moreover, these results were supported by the  DAISY study (Simpson et al., 2011). 
Still, genetic factors may also play a role in this case (Frederiksen et al., 2013; Norris 
et al., 2018).  
Severe emotional stress has been linked to the onset of T1D in the age group of 
5-9 years (OR 1.82, 95% CI 1.09-3.03) (Hägglöf et al., 1991). In the ABIS study 
(Nygren et al., 2015) where stress was measured prospectively in over 10,000 
participants, childhood experience of a serious life event was associated with a 
higher risk of T1D (HR 3.0, 95% CI 1.6-5.6 adjusted for age and heredity). Living 
in a war zone for over a month has been associated with an increased incidence of 
T1D in Israeli children (Zung et al., 2012).  
2.5.2 The HLA DR-DQ associated genetic risk of type 1 
diabetes  
The risk of T1D is known to be especially attributed to the class II HLA DR-DQ 
region on the short arm of the 6th chromosome. In addition to the association with 
T1D, the class II HLA is also linked to coeliac disease, birth weight and later obesity 
(Carlsson et al., 2012; Elding Larsson et al., 2016; Larsson et al., 2005; Yang et al., 
2014). Class II HLA DR3 has shown an association with clinical characteristics of 
T1D, such as a slower onset; it was described to spread more evenly over the years 
and presenting severe symptoms less often (Ludvigsson et al., 1986). 
The class II HLA molecule consists of α and β chain and form a heterodimer. 
These molecules are encoded by HLA-DR, -DQ and –DP loci. The function of class 
II HLA molecule is the presentation of antigens to T-cells. These heterodimers are 
present in antigen presenting cells, such as B-lymphocytes, dendritic cells and 
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macrophages. The slightly different structure of the different HLA molecules means 
that there is a different structure in the cleft that binds peptides. The HLA class II 
susceptibility alleles DQ2 and DQ8 for T1D have been described to form unstable 
complexes with most epitopes (Lee et al., 2001). 
The HLA genetic area is highly polymorphic meaning that there is a large 
variability of each gene in the population. Both susceptibility and protective DR-DQ 
associations with T1D are known (OR ranging from 0.02 to over 10) (Erlich et al., 
2008; Ilonen et al., 2016). The risk is especially high in DR3/4-DQ8 siblings who 
share their both HLA haplotypes with their diabetic proband sibling: by the age of 
15 years the risk of T1D is 85 % (Aly et al., 2006). HLA-DQB1*0602 allele is 
associated with dominant protection from diabetes also in islet cell antibody-positive 
first-degree relatives of patients with T1D (Pugliese et al., 1995).  
2.5.3 Genetic risk variants outside the HLA DR-DQ region  
In addition to the class II HLA region, multiple other loci have shown effect on the 
risk of T1D (Barrett et al., 2009; Groop & Pociot, 2014). The associations of other 
loci have been shown to include the progression rate to clinical onset of T1D or the 
appearance of autoantibodies (Lempainen et al., 2015). Adjacent to the HLA II 
region, class I HLA encodes molecules that are expressed in most cells of the human 
body and their functions include the presentation of peptides derived from the 
endoplasmic reticulum (ER) lumen. The presence of certain class I alleles has been 
found to influence T1D risk in the Finnish population (Mikk et al., 2017). 
The PTPN22 locus on chromosome 1p13 encodes for a lymphoid protein 
tyrosine phosphatase, nonreceptor type 22. This phosphatase manages the activity of 
immune cells and PTPN22 has been associated with the appearance of islet 
autoantibodies (Lempainen et al., 2015). Other PTPN22 associations include vitiligo 
(Canton et al., 2005), rheumatoid arthritis (Orozco et al., 2005) and thyroid diseases 
(Smyth et al., 2004). The protein tyrosine phosphatase, nonreceptor type 2 (PTPN2) 
(18p11.2) has been associated with the progression rate to clinical T1D after 
seroconversion in the DIPP study (Lempainen et al., 2015). A deficiency in PTPN2 
expression affects beta cell function in mice (Xi et al., 2015). 
Insulin gene (11p15) encodes for preproinsulin, a precursor of proinsulin. The 
association of between insulin gene and T1D was found in the 1980s (Bell et al., 1984). 
In the Finnish population insulin gene is one of the most strongly T1D associated genes 
outside the class II HLA region (Laine et al., 2013). Insulin gene did not affect the 
progression from autoantibody positivity to the clinical onset of T1D (Lempainen et al., 
2012). The promotor region of the insulin gene is a highly polymorphic area consisting 
of variable number of tandem repeats (VNTR) which are grouped into three classes 
according of their length: class I VNTR consists in approximately 30 to 60 repeats and 
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class III allele consists in 140-200 repeats. The class I and class III VNTR are the most 
common alleles in the Caucasian population. Insulin VNTRs have been associated with  
size at birth (Dunger et al., 1998; Ong et al., 1999) and growth (Bennett et al., 2004; 
Heude et al., 2006). During fetal development and early childhood, insulin gene 
expression at higher levels in the human thymus has been shown to be associated with 
class III alleles (Pugliese et al., 1997; Vafiadis et al., 1997). In the pancreas, class III 
VNTRs have been shown to be linked to a lower insulin transcription compared to class 
I alleles (Bennett et al., 1995; Vafiadis et al., 1996).  
The FUT2 gene encodes for fucosyltransferase 2, which synthesizes the ABO 
antigens in secretions and bodily fluids, such as saliva, tears, breast milk, gastric 
juice and gastrointestinal mucus. A nonfunctional gene (called non-secretors) has 
been shown to confer increased susceptibility to T1D and resistance to norovirus 
infection (Laine et al., 2013; Smyth et al., 2011). The prevalence of secretors was 
increased in rapid progressors with high risk HLA genotypes (Pöllänen et al., 2017). 
The secretor status has also been associated with the composition of intestinal 
microbiota: for example, non-secretors were less colonized by Bifidobacteria 
(Kumar et al., 2015; Wacklin et al., 2011). 
The gene encoding for cathepsin protease CTSH, a ubiquitously expressed 
lysosomal cysteine protease can be involved in overall protein turnover and specific 
cellular processes, such as apoptosis, antigen presentation, and prohormone 
processing. The CTSH genotypes are associated with the need for insulin in newly 
diagnosed T1D patients (Fløyel et al., 2014).  
Both ERBB3 and IKZF4 are located in the same region on the long arm of 
chromosome 12. Both genes have been associated with T1D (Hakonarson et al., 
2008; Laine et al., 2013; Todd et al., 2007). In more detail, the association between 
the IKZF4-ERBB3 region (12q13) and the development of T1D was observed in 
children with GADA as the first detected autoantibody (Lempainen et al., 2015). 
Both genes have also shown an inverse association with IAA positivity at diagnosis 
(Lempainen et al., 2013).  
2.5.4 Islet autoantibodies  
Islet autoantibody is a generic term that is used to describe any autoantibody that is 
targeted to the islets of Langerhans. Among islet autoantibodies are islet cell 
cytoplasmic antibodies (ICA) and biochemical autoantibodies (IAA, insulin 
autoantibodies; GADA, glutamic acid decarboxylase antibodies; IA-2A, insulinoma-
2-associated antibodies and zinc transporter 8 antibodies ZnT8A). The unspecific 
islet cell antibodies (ICA) were the first ones found in 1974 (Bottazzo et al., 1974; 
MacCuish et al., 1974).  
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Islet autoantibodies are considered as a marker of beta cell dysfunction, not 
pathological per se (Ziegler et al., 2013). In the follow up studies there has been a 
high incidence of appearance of islet autoantibodies already during the first years of 
life (Krischer et al., 2015; Parikka et al., 2012; Steck et al., 2011; Ziegler et al. 2012). 
The risk of T1D is low when ICA alone is present (Orban et al., 2009; Siljander et 
al., 2009). A single temporary ICA positivity was associated with a 5-year risk of 
1.4% (Siljander et al., 2009). Multiple islet autoantibodies are associated with 
strongly increased risk of T1D (Parikka et al., 2012; Siljander et al., 2009; Ziegler et 
al., 2013). This risk has been estimated to be over 40% in a 5-year follow up and 
over 80 % in a 15-year follow-up (Ziegler et al., 2013). Some studies have also used 
levels of islet autoantibodies in the prediction of T1D (Achenbach et al., 2004; Mrena 
et al., 2006; Steck et al., 2011). 
The immunofluorescence technique is used to detect ICA and identifies any 
antibody that binds to islet tissue, therefore it is not specific. The procedure involves 
sectioning of the pancreas from a human donor with an O blood type. The serum 
from the patient is incubated on these sections of cryocut pancreas and an antihuman 
immunoglobulin conjugate is added. Afterwards, when the slide is examined under 
a fluorescence microscope, the islets fluoresce if there are islet cell cytoplasmic 
antibodies present in the serum. ICA are expressed in terms of JDF (Juvenile 
Diabetes Foundation) units. 
Insulin autoantibodies (IAA) were found in 1983 in patients with recent onset of 
T1D (Palmer et al., 1983). As the first appearing autoantibody, the peak period for 
IAA is during the second year of life in the DIPP and TEDDY studies (Ilonen et al., 
2013; Krischer et al., 2015). Genetic associations with IAA have included the HLA-
DR4-DQ8 risk haplotype (Kimpimäki et al., 2001; Krischer et al., 2015; Sabbah et 
al., 1999) and the insulin gene polymorphism (Lempainen et al., 2015). 
As the major autoantigen of T1D, GAD65 (65 kDa isoform of glutamate 
decarboxylase GAD65) antibodies were identified in 1990 (Baekkeskov et al., 1990). 
As the first appearing autoantibody in DIPP and TEDDY children, GADA has been 
shown to peak between 3 and 5 years of age (Ilonen et al., 2013; Krischer et al., 
2015). The genetic associations with GADA have included the HLA-DR3-DQ2 
haplotype (Ilonen et al., 2017) and polymorphism in the IKZF4-ERBB3 region 
(Lempainen et al., 2015). An increase in the prevalence of GADA was observed by 
number of DQ2 haplotype in young age groups (Graham et al., 2002). 
The autoantibodies to IA-2 were initially characterized in 1995 in patients with 
recent onset T1D (Payton et al., 1995). IA-2 is a membrane protein found in the 
secretory granules of endocrine cells and neurons (Solimena et al., 1996). IA-2A has 
been associated with the HLA-DR4-DQ8 genotype (Gullstrand et al., 2008). 
ZnT8 is a recent major islet autoantigen discovered in 2007 (Wenzlau et al., 2008). 
It belongs to a family of zinc transporters and is localized in the insulin-containing 
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secretory granules where zinc forms a complex with insulin. ZnT8 plays an important 
role in this accumulation of insulin (Chimienti et al., 2006). ZnT8A were detected in 
63% of a group of Finnish children with T1D, with an inverse correlation with age at 
diagnosis: children diagnosed under the age of 5 were less likely to be positive for 
ZnT8 at the time of diagnosis than children in older age groups (Salonen et al., 2013). 
The frequency of ZnT8A was highest in those that carried neither DR3 nor DR4, but 
there was a positive relationship between ZnT8A and the class II HLA haplotype not 
associated with T1D ((DR13) ‐DQB1*0604) (Salonen et al., 2013).  
2.5.5 Changes in glucose metabolism  
When ICA positive relatives of T1D patients were followed for 7 years, a 
dysglycemic OGTT occurred at least once in 60% of the subjects during the follow-
up (Sosenko et al., 2009). Dysglycemia at the 6-month visit was highly predictive of 
T1D, especially in those aged less than 13 years (HR 5.4, 95% CI 3.6-8.1) (Sosenko 
et al., 2009).  
Most rapid rise in 2 h glucose OGTT in relatives of T1D patients (with either 
ICA and IAA or reduced FPIR) and rise of HbA1c as well as 2 h glucose in OGTT 
has been estimated to appear mostly during the last before diagnosis of T1D 
(Ferrannini et al., 2010). 
Prior studies in DIPP study children with multiple autoantibodies observed an 
increase in 2-hour glucose in OGTT 1.5 years before diagnosis of T1D (Helminen et 
al., 2015). Change in HbA1c was observed 2 years before the diagnosis T1D 
(Helminen et al., 2015). Random plasma glucose values started to rise 1.5 years 
before diagnosis and value ≥7.8 mmol/l was predictive of T1D in DIPP study 
children (HR 6.0, 95% CI 4.3-8.6) (Helminen et al., 2015). Impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT) were predictive of T1D (HR 3.2, 95% 
1.5-7.0; HR 8.3, 95% CI 6.0-11.5, respectively) (Helminen et al., 2015). 
There has not been much longitudinal data on the change of FPIR in preclinical 
period, although low FPIR value based on a single sample is clearly predictive of 
T1D (Bingley et al., 1996; Bingley et al., 2006; Siljander et al., 2013; Vardi et al., 
1991). In the T1D model (Eisenbarth, 1986), an initially normal insulin secretion 
capacity, has been suggested to decline linearly before diagnosis of T1D. In two 
earlier studies with small study population (Colman et al., 1998; Srikanta et al., 1984) 
a linear decrease in FPIR was observed before the onset of T1D. More recently, using 
longitudinal data on 74 high- risk subjects, Sosenko et al. reported an accelerating 
decline in FPIR about 1.5 to 0.5 years before the diagnosis (Sosenko et al., 2013). 
A single value of insulin resistance index determined by the homeostasis model 
assessment (HOMA-IR index) measuring insulin sensitivity (Matthews et al., 1985) 
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did not predict T1D but HOMA-IR adjusted to FPIR levels has been shown to be 
predictive of T1D (Fourlanos et al., 2004; Siljander et al., 2013; Xu et al., 2010). 
2.6 Prevention of type 1 diabetes 
Already in the 1980s it was observed that immune intervention in the form of 
cyclosporin (Feutren et al., 1986), anti-thymocyte globulin and prednisone 
(Eisenbarth et al., 1985), or with azathioprine and prednisone (Silverstein et al., 
1988) prolonged remission in T1D. However, the serious side effects of immune 
suppressants prevented their long-term use. In the 1990s, several small studies that 
included the use of cyclosporine, prophylactic insulin and nicotinamide (component 
of vitamin B3) showed effects in delaying the onset of T1D (Carel et al., 1996; Elliott 
et al., 1993; Ziegler et al., 1993). Modern primary and secondary prevention studies 
(Table 4) have included diet modifications or supplementations, antigen specific 
therapies and immunomodulators.  
Primary prevention studies are performed before there are signs of islet 
autoimmunity. Encouraging results were obtained from the FINDIA study with the 
use of bovine insulin free formula during the first 6 months of life (Vaarala et al., 
2012). The use of FINDIA formula was associated with a decreased risk of islet 
autoimmunity when compared to cow’s milk formula in 3 years and 6 years of 
follow-up (HR 0.24, 95% CI 0.08-0.72; HR 0.39, 95% CI 0.16-0.93, respectively). 
TRIGR (Trial to Reduce IDDM in the Genetically at Risk) study later investigated 
the use of hydrolyzed formula and the development of islet autoimmunity or T1D. 
Initially, hydrolyzed formula presented possible protection from the development of 
islet autoimmunity (Knip et al., 2010) but subsequent study results were negative for 
protection against the development of autoimmunity and T1D (Writing Group for 
the TRIGR Study Group et al., 2018).  
The TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study 
Group investigated the benefits of supplementation with docosahexaenoic acid 
(DHA) in children at high genetic risk for T1D (Chase et al., 2009). Supplementation 
of diets with DHA has resulted in increased DHA levels in red blood cells by at least 
20% at the age of 12 months (Chase et al., 2015). 
The German BABYDIET study analyzed whether a delay in the introduction of 
gluten would affect the development of islet autoimmunity in infants with genetic 
risk. The first gluten exposure was at the age of 6 months (control group) or at the 
age of 12 months (intervention group); during the 3 years of follow-up the 
intervention did not reduce the risk of islet autoimmunity (Hummel et al., 2011). A 
gluten-free diet for 18 months is currently being studied in subjects positive to at 
least one autoantibody and with signs of dysgclycemia in the TEFA (TEDDY Family 
Prevention) study (NCT02605148). 
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Despite negative results, the large-scale multicenter secondary prevention trials 
with oral/parenteral insulin or nicotinamide have increased the knowledge of T1D 
disease pathogenesis. The European Nicotinamide Diabetes Intervention Trial 
(ENDIT) study screened more than 30,000 relatives of patients with T1D (3-40 
years) for ICA in 354 clinical centers in 18 European countries, Canada and in USA. 
A total of 552 participants (252 participants under 15 years) were randomized to 
receive oral nicotinamide or placebo, but the intervention was ineffective (Gale et 
al., 2004). 
In the parenteral arm of the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) 
study, the effect of subcutaneous insulin was investigated in a randomized controlled 
nonblinded trial (Diabetes Prevention Trial-Type 1 Diabetes Study Group, 2002). 
Over 80,000 first- and second-degree relatives (3-45 years) of T1D patients were 
initially screened for ICA. After metabolic testing including OGTT and IVGTT and 
estimation of overall T1D risk, a total of 339 participants were randomly assigned to 
subcutaneous insulin and yearly 4-day continuous infusions of insulin. During 3.7 
years of follow up, a total of 139 subjects were diagnosed with T1D. The intervention 
was not effective (HR 0.96, 95% CI 0.69-1.34).  
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Table 4.  Type 1 diabetes intervention trials based on primary or secondary prevention 
strategies.  
Study (site)  Subjects Intervention Comment Reference  
TRIGR  
(Finland) 
 
newborn up to 6-8 
months of age 
casein hydrolysate 
formula  
pilot study showed 
effect in the 
development of 
autoimmunity  
(Knip et al., 2010)  
TRIGR 
(International) 
newborn up to 6-8 
months of age 
casein hydrolysate 
formula 
no effect on 
autoimmunity or 
T1D 
(Knip et al., 2014; 
Writing Group for 
the TRIGR Study 
Group et al., 2018) 
FINDIA 
(Finland) 
 
first 6 months of 
life 
whey based 
formula free of 
bovine insulin 
protection from 
the development 
of autoimmunity 
(Vaarala et al., 
2012).  
TrialNet  
(international) 
 
third semester or 
during the first 5 
months of life 
docosahexanoic 
acid DHA 
pilot study where 
safety and effect 
on RBC DHA 
levels were 
investigated   
(Chase et al., 
2009; Chase et 
al., 2015) 
BABYDIET 
(Germany) 
children <2 
months  
delay of 
introduction of 
gluten 
no effect (Hummel et al., 
2011) 
DIPP 
(Finland) 
young children at 
increased risk 
nasal insulin no effect on 
progression rate 
(Näntö-Salonen et 
al., 2008) 
DPT-1 
(USA, Canada) 
relatives of 
patients with T1D 
(3-45 yrs) 
parenteral insulin no effect on 
progression rate 
(Diabetes 
Prevention Trial–
Type 1 Diabetes 
Study Group, 
2002)  
DPT-1 
(USA, Canada) 
relatives of 
patients with T1D 
(3-45 yrs) 
oral insulin  post hoc analysis 
suggested 
protective effect in 
a subgroup (with 
high IAA titers) 
(Skyler et al., 
2005)  
TrialNet 
(International) 
subjects with IAA 
(median age 8 
years) 
oral insulin there was 
suggestive 
protective effect in 
subjects with low 
FPIR  
(Writing 
Committee for the 
Type 1 Diabetes 
TrialNet Oral 
Insulin Study 
Group et al., 
2017)  
ENDIT 
(International) 
ICA positive 
relatives of T1D 
patients 
(3-40 years) 
nicotinamide no effect on 
progression rate 
(Gale et al., 2004) 
Pre-POINT 
(Germany, 
Austria, USA, 
UK) 
children at high 
risk (2-7 yrs) 
oral insulin  pilot study 
investigated 
immune 
responses to 
insulin and 
adverse events  
(Bonifacio et al., 
2015)  
DiAPREV-IT 
(Sweden) 
subjects aged 4-
18 with GADA and  
another islet aab 
GAD-alum no effect on 
progression rate  
(Elding Larsson et 
al., 2018) 
TrialNet 
(International) 
8-50 years with ≥2 
islet aab 
teplizumab effect on 
progression rate 
(Herold et al., 
2019) 
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In the oral arm of the DPT-1 study, over 100,000 relatives of patients were screened 
and a total of 372 subjects with estimated 26-50 % risk of progression to T1D in 5 
years of follow-up received oral insulin or placebo. During the median follow-up of 
4.3 years, 97 participants were diagnosed with T1D. The intervention did not affect 
the progression to T1D (HR 0.76, 95% CI 0.51-1.14). However, an effect in a 
subcohort was observed, as among participants with confirmed high IAA titers 
(n=263) there were less progressors in the oral insulin group (HR 0.57, 95%CI 0.36-
0.89). The TrialNet study could not confirm this finding, but there was a protective 
effect in subjects (n=55) with low FPIR (HR 0.45, 95% CI 0-0.82) (Writing 
Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group et al., 2017). 
Oral insulin has also been studied in the PREPOINT study in young children without 
islet autoantibodies but with genetic risk (Bonifacio et al., 2015). Nasal insulin in 
young autoantibody positive children from the DIPP study did not prevent or delay 
the onset of T1D (Näntö-Salonen et al., 2008). A nasal insulin trial in 4-30 years old  
first- or second-degree relatives of T1D patients with two or more islet 
autoantibodies and a FPIR above the threshold is still ongoing in Australia 
(NCT00336674).  
Antigen-specific therapies have also included treatment with GAD. Children and 
adolescents (4-18 years) who were positive for GADA and at least one other 
autoantibody received two injections of GAD formulated in alum or placebo, but it 
did not affect the progression to the disease (Elding Larsson et al., 2018). 
More recently, teplizumab (an anti-CD3 monoclonal antibody) showed delaying 
effect of diabetes in 76 participants (8-50 years) with two or more islet 
autoantibodies (HR 0.41, (95% CI 0.22-0.78) with the median follow up 745 (74-
2683) days. The presence of HLA-DR4 and absence of DR3 or ZnT8 autoantibodies 
were associated with more robust responses to teplizumab (Herold et al., 2019). 
Teplizumab, as well as abatacept, have also showed beneficial effects in patients 
with recent onset T1D (Herold et al., 2002; Orban et al., 2011). A secondary 
prevention trial with abatacept is still ongoing in 6-45 year old subjects with two islet 
autoantibodies excluding IAA (NCT01773707). Other ongoing trials include 
methyldopa (NCT03396484) and the use of incretin liraglutide (NCT02898506).  
2.7 Beta cells of the pancreatic islets 
2.7.1 Anatomy and function 
In human pancreas (in Greek pan”all”, kreas ”flesh”) there has been estimated to be  
approximately 1.5 million of islets: the estimates have ranged a lot (from 1 million 
to 14.8 million) depending partly if the small islets are also included (Korsgren et 
al., 2005). In adults, pancreas weighs approximately 50-125 g and the exocrine 
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pancreas which takes part in digestion accounts for 98% of the total mass, thus the 
weight of the islets is only 1-2 grams. In addition to beta cells, islets contain four 
other cell types: alpha, delta, PP and more recently found epsilon cells (Gray et al., 
2019).  
Beta cells secrete insulin in a pulsatile fashion in 5-min cycles (Hellman et al., 
2009; Song et al., 2000). These insulin pulses may account for as much as 70% of 
total insulin secretion in the basal state (Hellman et al., 2009; Pørksen et al., 
1995).The gap junctions between beta cells are important in the electrical coupling 
and regulation of synchronous insulin secretion (Bavamian et al., 2007). While the 
main stimulus for beta cells to release insulin is elevated blood glucose, there are 
multiple extracellular factors including amino and fatty acids, neurotransmitters, 
hormones that can amplify insulin secretion (Henquin et al., 2003).  
The pancreas receives blood from branches of both the coeliac and superior 
mesenteric arteries (Jansson, 1994). Pancreatic islets are especially highly 
vascularized. The blood that leaves the pancreas goes to the splenic and the superior 
mesenteric veins, eventually leading to the portal vein. The thin-walled lymphatic 
vessels of the pancreas have a relatively large lumen and drain into the lymph nodes 
that are located around the organ and its surroundings (O'Morchoe, 1997). 
The islet structure in humans is different from that of a rodent (Barbieux et al., 
2016). In humans, beta cells are distributed, not cluttered and there is likely more 
paracrine interaction with other endocrine cells (Cabrera et al., 2006). Islets are 
innervated by parasympathetic (Rossi et al., 2005) and sympathetic fibers (Borden 
et al., 2013). The innervation of human islets has been described to be sparse and 
constituting mostly of sympathetic fibers (Rodriguez-Diaz et al., 2011). 
2.7.2 Embryogenesis 
During embryogenesis, beta cells are derived from the endoderm layer, which is one 
of the three layers forming the embryo, the other two being ectoderm and mesoderm. 
In humans, at approximately 5 weeks after conception two separate buds, dorsal and 
ventral, are formed from the endoderm. The expression of Pdx1 operates as a marker 
for the pancreatic bud development (Kim & MacDonald, 2002; Pan & Wright, 2011). 
The two buds fuse together later during gut rotation. The tail and body of the 
pancreas are derived from the dorsal part whereas the head is originated from both 
parts. Extracellular signals from neighboring cells contribute to this, and many of the 
transcription factors that regulate differentiation of beta cells have been identified 
(Cerf, 2006). The developing aorta and notochord give signals that induce the 
endodermal epithelium into pancreatic endoderm. Notch signaling in mice has been 
described to take part in the differentiation of progenitor cells into endocrine or 
exocrine cells (Apelqvist et al., 1999).  
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The beta cells have been the first endocrine cells detected during the 
development of human embryo (Piper et al., 2004). The vasculature and lymphatic 
network have been shown to be complete during the second trimester of the 
pregnancy (Roost et al., 2014). 
Intrinsic regulator Neurog 3 is essential for endocrine development in the 
pancreatic endoderm (Salisbury et al., 2014) and its expression increases rapidly 
after the embryonic period and coincides with the appearance of fetal beta cells 
(Jennings et al., 2013; Lyttle et al., 2008; Piper et al., 2004). A mutation in the 
Neurog3 gene has caused neonatal diabetes with severe congenital diarrhea (Rubio-
Cabezas et al., 2011) or isolated diarrhea with later T1D by 9 years of age (Wang et 
al., 2006). Thus, Neurog3 appears to play a role in the enteroendocrine cellular 
development. NEUROG3 activation through a mutation in STAT3 causes premature 
differentiation into endocrine cells (Saarimäki-Vire et al., 2017). Glis3 is a 
transcriptional regulator of endocrine cell progenitors (Kang et al., 2009) and 
mutations in GLIS3 have been associated with neonatal diabetes and congenital 
hypothyroidism (Senee et al., 2006).  
The human fetal pancreas has been shown to be responsive to glucose already 
during the first half of gestation, although the pulsatility of insulin only happens at a 
later stage of development (Otonkoski et al., 1988). A more recent study has 
observed that beta cells show endocrine functions already during the first trimester 
(Piper et al., 2004). The beta cell replication rate was high starting from the 9th week 
of gestation (Meier et al., 2010). The frequency of beta cell apoptosis was shown to 
be relatively high during prenatal life. 
2.7.3 Replication and function after birth 
Beta-cell replication is the primary mechanism used in the postnatal expansion of 
beta-cell mass in humans (Meier et al., 2008). Neogenesis happens mostly during the 
fetal period but has been shown to continue up to the first two years of life (Gregg 
et al., 2012). The baseline population of beta cells and their connections with other 
islet cells is set up before the age of 5 years (Gregg et al., 2012). However, in adults, 
new beta cells mainly originate from pre-existing beta cells by duplication (Dor et 
al., 2004). There is adaptive beta cell increase after pregnancy or body weight 
increase (Butler et al., 2010; Butler et al., 2007). It has been estimated that beta cell 
replication is mainly limited to the first three decades of life (Perl et al., 2010). 
In mice, it has been shown that a short-term glucose stimulus increases beta cell 
hypertrophy and hyperplasia (Bonner-Weir et al., 1989). Beta cell replication 
showed increase after immune therapy in mice, but the recovery of the beta cell area 
was mostly attributed to the regranulation of beta cells with insulin (Sherry et al., 
2006).  
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The exact quantification of beta cell mass in humans is still difficult. Early 
studies have noted that beta cells are still present in T1D patients; moreover, islet 
hyperplasia was also observed (Maclean & Ogilvie, 1959). Autopsy data from young 
recent onset T1D cases revealed that most of them (14 out of 16) had beta cells; 
moreover, in 25 % of cases, it was described that there was a relatively large number 
of beta cells still present (Gepts & De Mey, 1978). Signs of islet regeneration were 
found in many T1D cases and beta cells were described as hyperactive with high 
RNA but low insulin content in the cytoplasm (Gepts & De Mey, 1978). 
In very young children with an acute onset and ketoacidosis there were only a 
few beta cells present, and the degree of insulitis differed between subjects 
(Lernmark et al., 1995). The beta cell area and mass were significantly higher in T1D 
donors who had insulitis, compared to those without insulitis (Campbell-Thompson 
et al., 2016). Insulitis means lymphocytic infiltration of  islets and is now defined by 
the presence of a minimum of 15 CD45+ cells in at least  three pancreatic islets 
(Campbell-Thompson et al., 2013). 
2.8 Glucose metabolism  
Throughout the regulation of glucose metabolism,the  pancreas interacts with many 
other organs. The functions of each organ in glucose metabolism are different and 
depend on many factors, such as the duration of fasting, activity levels, as well as 
the circadian rhythm (Colberg et al., 2010; Mattson et al., 2014). In the anticipation 
of a meal, a cephalic phase of insulin secretion occurs even before food is introduced 
(Caumo & Luzi, 2004). This phase has been shown to be important in postprandial 
glucose management (Ahrén & Holst, 2001).  
Approximately 20 % of the energy derived from glucose is used by the brain 
(Mergenthaler et al., 2013). Glucose sensors in the brain and in the hepatic portal 
system help maintaining glucose homeostasis and correcting possible hypoglycemia. 
Glucose sensing neurons in the brainstem and hypothalamus react to decreased 
glucose availability by, for example, activating the sympathetic nervous system 
(Myers & Olson, 2012). The glucose sensing neurons in the hypothalamus may be 
particularly important in controlling the first phase of insulin secretion (Osundiji et 
al., 2012).  
Glucose molecules (molecular formula C6H12O6) can be found in sucrose (the 
“common” sugar), where they are bound to fructose and in starch where they form 
straight amylose chains or branched amylopectin chains. Fructose has the same 
molecular formula as glucose, but with a five-membered ring structure. In human 
digestion, carbohydrates are first hydrolyzed to monosaccharides, which starts in the 
mouth, but mostly occurs in the small intestine. Carbohydrates that are not digested 
in the small intestine are anaerobically metabolized by bacterial flora in the large 
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intestine. Despite having the same chemical formula as starch, cellulose has a 
different structural formula (each successive glucose monomer is positioned at 180 
degrees around the axis), making it indigestible in humans (Cummings, 1984). 
Gastrin, secreted by the stomach, may play a significant  role in the stimulation of 
insulin release during protein rich meals (Rehfeld & Stadil, 1973). 
Glucose is transported from the intestinal lumen into enterocytes by the 
Na+/glucose cotransporter (SGLT1), although glucose transporter type 2 (GLUT2) 
may also play a role. Enzymes that hydrolyze carbohydrates are secreted by the 
intestinal cells that line the villi. The gastrointestinal tract also releases hormones, 
called incretins that stimulate insulin secretion (Bradley et al.,2011; Rehfeld, 2018).  
The circulating glucose is then taken up by a glucose transporter, and beta cells 
in the pancreatic islets have been shown to use mainly GLUT 1 and GLUT 3 
transporters whereas GLUT 2 is the main transporter in rodents (De Vos et al., 1995; 
McCulloch et al., 2011; Rorsman & Braun, 2013). However, mutations in SLC2A2 
gene that encodes GLUT2 can cause neonatal diabetes, thus GLUT2 probably also 
has a role in human insulin secretion (Sansbury et al., 2012). 
When glucose enters beta cells, it is phosphorylated by glucokinase (GCK). This 
is the first step in the glycolytic pathway as the glucose is converted to glucose 6-
phosphate. Type 2 of MODY (maturity onset diabetes of the young) is caused by a 
mutation in the GCK gene (Froguel et al., 1992). In MODY2 the threshold for 
initiation of glucose-stimulated insulin secretion is altered and fasting glucose levels 
are usually slightly elevated.  
By releasing insulin, the pancreas regulates the storage of glucose in the liver. In 
glycogenesis glucose molecules are joined to the glycogen chains of multibranched 
glucose polysaccharides. The liver maintains glucose homeostasis by absorbing and 
storing glucose after meals. The absorbed glucose in liver is converted into glucose 
6-phosphate by specific kinases. HNF1a is a transcription factor highly expressed in 
the liver and regulates the expression of many hepatic genes. HNF1a is also 
expressed in the pancreas, and HNF1a-deficient mice have impaired insulin secretion 
(Pontoglio et al., 1998). Importantly, a mutation in the gene that encodes this protein 
is associated with one type of MODY (HNF1A-MODY)(Vaxillaire et al., 1997). 
The liver also releases glucose in a contolled manner between meals (through 
glycogenolysis, the removal of glucose residues in the form of glucose-6-
phosphatase from glycogen). By releasing glucagon from alpha cells, the pancreas 
regulates the release of glucose by the liver. Gluconeogenesis, glucose production 
from non-carbohydrate sources such as glucogenic amino acids or triglycerides 
occurs in the liver and kidney. Muscles have a large storage of glycogen and GLUT4 
facilitates glucose uptake in this tissue. In adults with type 2 diabetes (T2D), GLUT4 
protein content and glucose disposal were increased after seven days of exercise 
training (O'Gorman et al., 2006). The secretion of glucocorticoids that can be a result 
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of stress and hypothalamic-pituitary-adrenal axis activation seems to decrease 
glucose transport in skeletal muscle by lowering insulin-stimulated GLUT4 
translocation and that may induce insulin resistance (Dimitriadis et al., 1997; Qi & 
Rodrigues, 2007).  
2.9 The first phase insulin response 
After removal of the signal peptide from  preproinsulin in the ER, the proinsulin is 
packaged into small granules in the Golgi complex. These granules are located at 
least in two different intracellular pools within the beta cell. Apart from the reserve 
pool, a small fraction of the granules locates in the proximity of the cell membrane 
in the readily releasable pool. These granules contribute to FPIR (Daniel et al., 1999; 
Olofsson et al., 2002) representing the increase of insulin values during the first ten 
minutes in IVGTT. In addition to glucose, other pharmacological agents such as 
tolbutamide and arginine have been used to trigger insulin secretion (Henquin et al., 
2003). 
An increase in  extracellular glucose concentrations leads to a cascade  that 
results in an influx of Ca2+ in beta cells which, in turn, triggers the fusion of insulin 
granules to the plasma membrane and the activation of exocytotic machinery 
(Henquin et al., 2003). The increased ATP/ADP ratio in the cell due to the glycolytic 
process closes ATP-dependent K+ channels, the subsequent depolarization of the 
membrane opens the voltage-dependent Ca2+ channels (Henquin et al., 2003). The 
maximum exocytotic rate in a single beta cell has been shown to be reached in 26 
ms after depolarization (Barg et al., 2001). 
The mechanism of transportation of insulin granules to the proximity of the 
plasma membrane is not completely known, however, it apparently involves specific 
motor proteins and translocation along microtubules (Varadi et al., 2003). The fusion 
of insulin granules to the membrane is mediated by members of the SNARE protein 
superfamily (Hastoy et al., 2017). In mice approximately 7% of a total of 9000 
insulin granules have been estimated to be docked below the plasma membrane 
(Olofsson et al., 2002). Glucose stimulates docking of the granules to the membrane 
(Straub, et al., 2004). Dissociation of C-peptide and mature insulin occurs after the 
release of the insulin granules from the beta cell as proteases split proinsulin into 
equal amounts of insulin and C-peptide. The FPIR is followed by a gradually 
developing ATP-dependent second phase (5-60 min) to the same release site that 
requires translocation of the reserved granule pool to the plasma membrane. A more 
prolonged glucose stimulation with the second phase release has been described to 
compensate for a low FPIR (Cerasi & Luft, 1967). 
Age, pubertal status and ethnicity affect FPIR (Lorini & Vanelli, 1996; Smith et 
al., 1988, Arslanian & Suprasongsin, 1996; Gower et al., 2002; Xie et al., 2010). 
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Normally, FPIR increases over time in healthy children and adolescents (Allen et al., 
1993). and it has shown correlation with body mass index (Allen et al., 1993; Gerich, 
2002; Gungor et al., 2004). Cardiorespiratory fitness has also been found to be 
associated with insulin response in healthy children, depending on total adiposity 
(Lee et al., 2006). Estimates of beta cell mass have been correlated with FPIR (Hao 
et al., 2017; Larsen et al., 2006; McCulloch et al., 1991).  
There is variation in FPIR between and within subjects (Smith et al., 1988). The 
area under the 0-10 min curve showed less between-subject variation in healthy 
adults (Smith et al., 1988) The within-subject variation between two tests that were 
taken 2 weeks to 4 months apart was only 4% in FPIR and 6.7% in the area under 
the 0-10 min insulin curve (Rayman et al., 1990). Good reproducibility associated 
with low values may be a sign of “non-normality” (Soeldner, 1988) and the 
importance of more than one low FPIR value has been emphasized (Chase et al., 
1991; Ismail et al., 2015). A standardization of IVGTT was developed in 1992 to 
overcome problems regarding the heterogeneity in the methods such as glucose dose 
and infusion time (Bingley et al., 1992). In general, the correlation of FPIR values 
in young subjects has been moderate-good, ranging from 0.74 to 0.87 (Keskinen et 
al., 2002; Robert et al., 1991; Vialettes et al., 1988).  
The relationship between FPIR and insulin sensitivity has been described as 
hyperbolic (Kahn et al., 1993). Thus, any changes in insulin sensitivity are associated 
with small or large changes in insulin secretion depending on insulin sensitivity 
(Kahn et al., 1993). The correlation coefficient between insulin response and insulin 
sensitivity has ranged from 0.21 to 0.39 depending on the degree of glucose tolerance 
(Ferrannini et al., 2011).  
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3 Aims of the study 
The main aims of this study were  
1. To study beta cell function, measured as first phase insulin response (FPIR), 
from the onset of islet autoimmunity in a longitudinal setting with several 
measurements in DIPP children that progressed to T1D (progressors) and in 
DIPP children with ICA only and remaining healthy (non-progressors) (study 
I)  
2. To compare FPIR values during the childhood between progressors and non-
progressors (study I)  
3. To study the associations between FPIR, autoantibodies and the class II HLA 
DR DQ genotypes (study II) 
4. To study the associations between FPIR and genetic variants outside the class 
II HLA DR DQ region (study III) 
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4 Materials and methods 
4.1 DIPP study 
The Type 1 Diabetes Prediction and Prevention (DIPP) study was launched in 1994 
in Turku and during the following years also in Oulu and Tampere. 
The DIPP study protocol includes the screening of the newborn for class II HLA-
conferred genetic T1D risk (chapter 4.3). Eligible children are invited to the study 
and followed regularly. During the first two years of life, study visits are performed 
every 3-6 months. After that, visits are performed every 6-12 months. However, if 
islet autoantibodies are detected, the frequency of study is returned to every 3 
months.  
Since 1994, over 230, 000 newborn children have been screened for the genetic 
risk of T1D (J. Ilonen, personal communication). The HLA screening criteria have 
slightly changed during the DIPP study (Chapter 4.3). 
4.2 Study subjects 
Study children (Figure 1) were participants of DIPP study from Turku, Oulu and 
Tampere centers. Originally, a total of 685 children had undergone an IVGTT after 
the appearance of autoantibodies during years 1996-2012. 
Study I included altogether 402 children. Of these, a total of 192 children (116 
male, 60.4%) had developed only classical ICA at the median age at seroconversion 
of 4.6 (0.7-12.6) years and remained healthy during the follow-up (non-progressors). 
The remaining 210 children had developed T1D during the follow-up (progressors). 
Of the 210 progressors (117 male, 55.7%), 17 children had been originally recruited 
as siblings (they had been recruited when the index child entered the study). In 193 
index progressors the median (min-max) age at seroconversion was 1.6 (0.5-10.6) 
years and the median (min-max) age at the time of appearance of multiple islet 
autoantibodies was 2.0 (0.8-10.6) years. ICA was included in the definition of multiple 
autoantibodies. The age at diagnosis in 210 children was 6.6 years (range 1.6-16.1 
years). A total of 155 children had been involved in the nasal insulin trial (Näntö-
Salonen et al., 2008). There were no differences in the baseline FPIR or in the change 
from the baseline FPIR to the last FPIR between the placebo and nasal insulin groups. 
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Figure 1.  The study flowchart.  
Studies II and III originally included 574 children that had been fully genotyped for 
class II HLA DR-DQ conferred T1D risk. Those subjects who had their first IVGTT 
performed during the last 2 years prior to diagnosis were excluded from the analysis 
in order to avoid the strong influence of a late preclinical decrease in FPIR. This 
resulted in 514 children as 60 progressors from the initial data set were not included 
since these children developed T1D in less than 2 years from their first IVGTT.  
The 514 children were categorized according to their islet autoantibody status 
based on the presence of biochemical islet autoantibodies (IAA, IA-2A, GADA or 
ZnT8A) or ICA only (later referred to as no biochemical autoantibodies) at the time 
of the first IVGTT. Data on ZnT8A was available from 509 (99.0%) of the subjects. 
Children initially with zero or one biochemical islet autoantibody but with additional 
biochemical autoantibody at other age points were analyzed separately (76 children). 
Thus, a total of 438 children were included in the hierarchical linear mixed model in 
studies II and III. Of these, 205 children were persistently negative for biochemical 
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autoantibodies, 38 were positive for only a single biochemical autoantibody and a 
total of 195 children had two or more biochemical autoantibodies at the time of the 
first IVGTT. In the study cohort of 438 children who remained in the initial 
autoantibody group (268 males, 61.2%), the median (IQR) age at the first IVGTT 
was 4.6 (2.7-7.3) years. The total number of IVGTTs in these children was 1149. 
4.3 Genetic analyses and risk categorization (study 
II)  
HLA-DR/DQ genotyping was performed stepwise beginning from definition of 
HLA-DQB1 alleles and expanded thereafter to cover informative DQA1alleles and 
in the case of DQA1*03-DQB1*03:01 and DQB1*03:02 haplotypes also various 
DRB1*04 alleles. The details of the methods and procedure have been described 
earlier (Kiviniemi et al., 2007; Ilonen et al., 2013). 
As the knowledge of the HLA-risk associated DR/DQ haplotypes and screening 
criteria have evolved it was learned that some of the DIPP children invited to regular 
follow-up carry genotypes associated with neutral or even decreased T1D risk 
despite being initially classified as carrying increased risk-associated DQB1 alleles. 
However, children with the most common strongly protective HLA-DQB1*06:02 
allele (Pugliese et al., 1995) have not been eligible for the DIPP follow-up.  
The risk of T1D can now be divided into six different categories: highly, 
moderately or slightly increased risk, neutral risk and groups with slightly decreased 
or strongly decreased risk (Ilonen et al., 2016). This categorization is based on the 
presence of DR/DQ haplotypes associated with the disease risk observed in the series 
of the Finnish Pediatric Diabetes Register (Ilonen et al., 2016, Table 5a-b). 
The highly increased risk is the combination of the DR3 ((DR3)-DQA1*05-
DQB1*02) and DR4 (DRB1*04:01/2/4/5-DQA1*03-DQB1*03:02) haplotypes. The 
moderately increased risk means a combination of DRB1*04:01/2/5-DQA1*03-
DQB1*03:02, the stronger risk haplotype together with a neutral haplotype. The 
slightly increased risk means combinations of lower risk haplotypes DRB1*04:04-
DQA1*03-DQB1*03:02 or (DR3)-DQA1*05-DQB1*02 with a neutral haplotype or 
a combination of the strong risk haplotype with a weakly protective haplotype. 
Neutral risk associated genotypes are various combinations of neutral haplotypes or 
combinations of a risk and a protective haplotype, and decreased risk associated 
genotypes are combinations of neutral and protective haplotypes or various 
protective haplotypes. In study II, the groups with a neutral risk, slightly decreased 
risk and strongly decreased risk were combined for analyses, thus resulting 
altogether in four different risk groups. 
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Table 5 a-b.  The risk of type 1 diabetes in different HLA DR-DQ haplotypes (a) and combinations 
of haplotype risk in genotype risk groups (b). ↑↑, strong susceptibility; ↑, weak 
susceptibility; ↔, neutral; ↓ , weak protection; ↓↓, strong protection. Modified from 
Ilonen et al., 2016. 
a 
Class II HLA DR-DQ haplotype Risk 
Su
sc
ep
tib
ilit
y 
ha
pl
ot
yp
es
 
DRB1*04:01-DQA1*03-DQB1*03:02 ↑↑ 
DRB1*04:05-DQA1*03-DQB1*03:02 ↑↑ 
DRB1*04:02-DQA1*03-DQB1*03:02 ↑↑ 
DRB1*04:04-DQA1*03-DQB1*03:02 ↑ 
(DR3)-DQA1*05-DQB1*02 ↑ 
N
eu
tra
l a
nd
 p
ro
te
ct
iv
e 
ha
pl
ot
yp
es
  
(DR13)-DQB1*06:04 ↔ 
(DR9)-DQA1*03-DQB1*03:03 ↔ 
(DR8)-DQB1*04 ↔ 
(DR16)-DQB1*05:02 ↔ 
(DR7)-DQA1*0201-DQB1*02 ↔ 
(DR1/10)-DQB1*05:01 ↔ 
(DR4)-DQA1*03-DQB1*03:01 ↔ 
(DR13)-DQB1*06:09 ↔ 
DRB1*0403-DQA1*03-DQB1*03:02 ↓ 
(DR13)-DQB1*06:03 ↓ 
(DR11/12/13)-DQA1*05-DQB1*0:301 ↓ 
(DR7)-DQA1*02:01-DQB1*03:03 ↓↓ 
(DR15)-DQB1*06:01 ↓↓ 
(DR15)-DQB1*06:02 ↓↓ 
 (DR14)-DQB1*05:03 ↓↓ 
b 
Haplotype risk combinations Class II HLA genotype risk group 
↑↑ / ↑ , ↑ / ↑ (if different, both DR3 
and DR4 haplotypes) High risk 
↑↑ / ↑ , ↑ / ↑ (if same haplotypes, 
two DR3 or two DR4), 
↑↑ / ↑↑ and ↑↑ / ↔ 
Moderately increased risk  
↑ / ↔  and  ↑↑ / ↓  Slightly increased risk  
↔ / ↔, ↑↑ / ↓↓, ↑ / ↓↓ and ↑ / ↓ Neutral 
↓ / ↔ Slightly decreased risk 
↓↓ / ↔, ↓ / ↓, ↓↓ / ↓ and ↓↓ / ↓↓ Strongly decreased risk  
Maarit Koskinen 
 38
4.4 Genetic variants outside the class II HLA DR-
DQ region (study III) 
The eight SNP markers IFIH1 (rs1990760), ERBB3 (rs2292239), INS (rs689), 
IKZF4 (rs1701704), PTPN2 (rs45450798), FUT2 (rs601338) CTSH (rs3825932) and 
PTPN22 (rs2476601) were genotyped by using the Sequenom (San Diego, 
California, USA) platform (University of Eastern Finland, Kuopio, Finland) 
(Lempainen et al., 2015) or Taqman SNP Genotyping Assay (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) (CTSH rs3825932). The assays of class I 
HLA alleles (B*39, A*24) were analyzed on the DELFIA platform (Mikk et al., 
2014; Mikk et al., 2017).  
4.5 Islet autoantibody measurements 
The islet autoantibody measurements in the DIPP study has been performed in the 
Diabetes Research Laboratory, University of Oulu and includes the detection of IAA, 
GADA, IA-2A and ICA as described earlier (Siljander et al., 2009). In addition, 
ZnT8A have been measured from all subjects positive for other islet autoantibodies 
by a radiobinding assay in the University of Helsinki (Salonen et al., 2013). 
4.6 IVGTT protocol 
A standard protocol was followed (Bingley et al., 1992) Children underwent IVGTTs 
after overnight fasting. A local anesthetic (EMLA, AstraZeneca, Södertälje, 
Sweden) was used before the cannulation. The fasting samples were drawn through 
an intravenous cannula 5 and 0 min before the start of the glucose infusion. The 
glucose dose was 0.5 g/kg (maximum 35 g). Glucose was infused through the 
cannula in 3 min ± 15 s, and samples were subsequently taken at 1, 3, 5, and 10 min 
(in Turku center also at 30 and 60 minutes) after the end of the infusion (Keskinen 
et al., 2002).  
4.7 Laboratory measurements 
Plasma glucose concentrations were measured by an enzymatic method (Beach & 
Turner , 1958).For the quantitative serum insulin measurements an ELISA (Insulin 
ELISA Kit, Dako, Glostrup, Denmark) method (Andersen et al., 1993) was used in 
the Diabetes Research Laboratory, University of Oulu for samples obtained in Oulu 
and Tampere. In Turku, the method for serum insulin measurement has changed 
twice during the DIPP study (described in detail in the study I). The current method 
is an electrochemiluminescence immunoassay (ECLIA, Roche Diagnostics). The 
insulin assays in the Oulu and Turku laboratories have been compared before 
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(Keskinen et al., 2002) and a regression transformation equation was used to make 
the values from the Oulu laboratory comparable with the Turku radioimmunoassay 
(RIA) values. The insulin concentrations obtained with the more recent Turku assays 
were also corrected to make them comparable with the concentrations generated with 
the initial Turku RIA. 
4.8 Markers of glucose metabolism  
Beta cell function was evaluated by FPIR (study I-III) and the area under the 0 to 10 
min insulin curve (AUC0-10 min for insulin, study I). As surrogate markers for insulin 
sensitivity (study I), fasting insulin concentrations, the HOMA-IR index and the 
HOMA-IR to FPIR -ratio (relative insulin resistance) were used. HOMA-IR index is 
calculated as (fasting glucose x fasting insulin)/22,5. Fasting values for insulin and 
glucose (study I) were calculated as the mean of 5- and 0-min values from the 
IVGTT. When the fasting insulin values were below the detection limit, that limit 
was used as an actual value. Glucose at 60-minute values from Turku data set were 
analyzed to investigate the late-phase glucose values (study I). 
The first phase insulin response (FPIR) was calculated as the sum of insulin 
concentrations at 1 and 3 minutes during IVGTT. We also calculated as an additional 
variable ΔFPIR based on the change in FPIR: the last FPIR minus the first FPIR 
divided by the time between the samples (in years).  
4.9 Statistical analyses 
The response variables (glucose metabolism markers) were log-transformed for the 
analyses to achieve the normality assumption in the statistical model.  
In study I, the scatterplots between age and response variables were noisy, so the 
data was explored using cubic splines (Reinsch, 1967). The time periods of 0-2 years, 
2-4years and 4-6 years before diagnosis (progressors) or the last IVGTT (non-
progressors) were analysed separately. The progressors’ last response variable 
before the diagnosis was compared with the previous one by a paired samples t-test. 
Non-parametric tests were used when appropriate.  
The effect of age on response variables was assessed by a linear mixed model. 
Predictor variables were age, group and their interaction. Given estimates for age 
represent how response variables change when age is increased by one year. Study 
variables between the study groups were compared at the ages of 2, 4, 6, 8, and 10 
years. In the age-dependent comparison, the difference between the study groups 
describes how many percent the response variable has changed in non-progressors 
compared to progressors. Analyses were performed excluding data from the last 2 
years prior to diagnosis in the progressors. 
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One-way ANOVA was used to compare markers of glucose metabolism at the 
time of 2 (±1) years prior to diagnosis in children categorized by their first appearing 
biochemical islet autoantibody (IAA, IA-2A or GADA). 
In study II, the relationship between autoantibody status and HLA risk was 
analyzed with Chi Square test. Class II HLA risk was treated as a categorical variable 
1-4. Cochrane Armitage test was applied to study the trends of two-categorical 
autoantibody groups in different class II HLA groups. Hierarchical linear models 
were used to analyze repeated measurements of FPIR. The statistical models 
included HLA and autoantibody status groups, as well as interaction terms HLA by 
time and autoantibody group by time. The number of IVGTTs decreased notably 
after 5 years from the first test, so the time period of 0-5 years from the first IVGTT 
was selected. The total number of IVGTTs in this period was 1023 (89.0% of all). 
Study III also used hierarchical linear mixed model. The model included islet 
autoantibody status, age, and the genotype for each of the loci analyzed (three/two 
groups). Three types of models (additive, recessive or dominant) were applied.   
Statistical analyses were performed with JMP Pro version 11.2 and SAS version 
9.4. P values of less than 0.05 (two-tailed) were considered statistically significant.  
4.10 Ethical aspects 
The study was conducted according to the guidelines of the Declaration of Helsinki. 
It was approved by the local Ethics Committees and a written informed consent from 
the families was provided for the study. 
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5 Results and discussion 
5.1 Longitudinal changes of FPIR after the onset of 
islet autoimmunity (study I) 
The aim of study I was to investigate FPIR during the preclinical period of T1D from 
the onset of islet autoimmunity. A total of 210 DIPP study children had progressed 
to T1D during the follow-up (progressors) while 192 children had only ICA and 
remained healthy (non-progressors).  
5.1.1 Longitudinal changes of FPIR before type 1 diabetes 
(study I) 
The declining median values of FPIR before the diagnosis of T1D are shown in 
Figure 2 (black solid line). When comparing the last two samples before diagnosis 
of T1D, there was a significant decrease of FPIR (p<0.005). Compared to non-
progressors (dotted line in Figure 2), FPIR was decreased in progressors up to the 
time period of 4-6 years before the diagnosis of T1D (p<0.005). We could not detect 
a difference in FPIR or other studied markers between the groups at the time of 2 
(±1) years before T1D based on the first appearing autoantibody. 
 
Figure 2. The median values of FPIR before the diagnosis of type 1 diabetes in the progressors 
(black line) and in the non-progressors until the last IVGTT (dotted line). The x axis 
indicates years before the diagnosis or the last IVGTT (point 0). Figure from Koskinen 
et al., 2016, used under the Creative Commons CC by 3.0 licence.  
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These results showed the overall declining pattern of FPIR before the diagnosis 
which is in line with previous studies (Chase et al., 1991; Colman et al., 1998; 
Srikanta et al., 1984). The decline of FPIR may be more rapid approximately year 
before diagnosis which has also been observed in the DPT-1 study (Sosenko et al., 
2013). It has been speculated that the loss could  be more gradual (Sosenko et al., 
2013). Similarly, in our study the change in FPIR between the last two samples was 
significant. Because of the long follow up time, however, both the timing of the last 
sample (median time 2.9 years before diagnosis; range 5 days-14 years) and time 
between the last two samples (median time 1.1 years; range 0.2-4.7 years) varied a 
lot so there can be subjects with more gradual loss in FPIR.  
We were able to obtain new information when we could compare the progressors 
to children with only ICA (non-progressors). Compared to non-progressors we could 
observe a difference in FPIR between the groups up to the time period of 4-6 years 
before the diagnosis. 
5.1.2 Longitudinal changes of FPIR in an age-dependent 
comparison 
We then investigated FPIR in the longitudinal age-dependent comparison (Figure 
3). The difference in FPIR between the progressors and non-progressors was 
significant in all age groups (p<0.001). FPIR was significantly higher in the non-
progressors than in the progressors, and the difference between the groups increased 
with age. At 2 years the difference was 50% (95% CI 28%-75%) and at 10 years 
difference was 172% (95% CI 128%-224%).  
 
Figure 3.  Mean values of FPIR shown in cubic splines between the non-progressors and 
progressors as a function of age (years). The solid lines show the values of the 
progressors with the last 2 years prior to diagnosis included (grey line) or excluded 
(black line). The black dotted line represents the non-progressors. Figure from Koskinen 
et al., 2016, used under the Creative Commons CC by 3.0 licence.  
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Taken together, children progressing to T1D had significantly lower mean values of 
FPIR throughout the childhood. The difference between the groups increased by age 
as the mean FPIR was almost three times greater in the non-progressors than in the 
progressors at the age of 10 years.  
In children presenting with only islet cell antibodies the risk of T1D is known to 
be low and these children had increasing FPIR over time. This is in line with the 
results from a previous study in healthy children (Allen et al., 1993). The difference 
between the groups at the age of 2 years was already 1.5-fold between the 
progressors and the non-progressors. In the DIPP study it has previously been 
observed that the increase of FPIR was seen less often in very young autoantibody 
positive children with FPIR below the 5th percentile compared to those who had 
FPIR above the 5th percentile (Keskinen et al., 2002) which could imply decreased 
capacity to increase insulin secretion over time in these children. 
Furthermore, ICA-negative siblings of patients with T1D were described to have 
significantly lower FPIR from 8 years onwards when compared to control children 
which could implicate a  defect in the growth of beta cell mass or insulin secretion 
(Carel et al., 1993). Indeed, the difference between the progressors and non-
progressors was significant already at an early age and the difference in the capacity 
to secrete insulin became more pronounced over time. It would be reasonable to 
search for a specific defect in the beta cell function in children that progress to T1D. 
5.2 Associations between FPIR, class II HLA risk 
and autoantibodies (study II) 
The class II HLA region is known to have the strongest association with T1D risk so 
in study II we aimed to search for the associations with class II HLA and FPIR. 
Children (n=438) were categorized by the presence of autoantibodies at the time of 
the first IVGTT and by the class II HLA conferred T1D risk. It was hypothesized 
that the effect of HLA risk group on FPIR would be explained by the appearance of 
islet autoantibodies. 
5.2.1 Associations between class II HLA risk and islet 
autoantibodies  
First, the relationship between islet autoantibodies and class II HLA genotype 
conferred genetic risk was studied. There was an association between class II HLA 
risk group and autoantibody status (p<0.0001 in Chi-Square test). Furthermore, there 
was a significant difference in the proportions of the HLA risk groups when 
comparing children with no biochemical autoantibodies to those with a single 
biochemical autoantibody or those with multiple biochemical autoantibodies 
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(p<0.02 and p<0.0001, respectively, Cochrane Armitage trend test). There was no 
statistically significant difference in the HLA risk group distribution when 
comparing children with single autoantibody to those with multiple biochemical 
autoantibodies (p=0.08).  
5.2.2 Associations between FPIR and the class II HLA risk 
When the change of FPIR over time was analyzed, the class II HLA risk was initially 
investigated alone in the model. The median FPIR over time was different between 
HLA groups (p=0.008), but not when effect of time was included in the model 
(p=0.50). When the autoantibody group with time interaction were added to the 
model, HLA risk grading did not anymore significantly associate with FPIR (p=0.26) 
nor FPIR change over time was significant between the HLA groups (p=0.35).  
 The class II HLA genotypes are associated with the initiation of autoimmunity 
(Ilonen et al., 2016). Previous studies have observed an association between class II 
HLA conferred strong genetic risk and multiple islet autoantibodies (Ilonen et al., 
2016; Knip et al., 2002; Siljander et al., 2009). Furthermore, the genotypes 
conferring decreased risk are less common among the autoantibody positive subjects 
(Knip et al., 2002). 
Thus, the class II HLA genotypes are associated with the initial levels of FPIR 
but the change of FPIR over time is further associated with the number of 
autoantibodies. An earlier study has also shown that the HLA DQB1 genotypes 
conferring increased T1D risk were associated with lower levels of FPIR (Veijola et 
al., 1995). The increase of FPIR over time was slower in DQB1 risk genotype 
carriers and these changes were also associated with the presence of autoantibodies 
(Veijola et al., 1995). 
5.2.3 Associations between FPIR and islet autoantibodies 
When the autoantibody status was included in the model in the current study, lower 
FPIR was strongly associated with the positivity for multiple biochemical 
autoantibodies in both HLA-adjusted and HLA unadjusted models. (p<0.0001 for 
both). There was a significant interaction by time as the change of FPIR over time 
was significantly different between children with multiple autoantibodies and those 
with single or no autoantibodies (p<0.0001). Children with multiple autoantibodies 
had decreasing FPIR and children with 0 or 1 autoantibody had increasing FPIR 
(Figure 4). 
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Figure 4.  FPIR over time in children with various number of biochemical islet autoantibodies (0, 
single or multiple). The Y-axis shows FPIR on a logarithmic scale. X-axis shows time 
from the first FPIR. Coefficient estimates are -0.00020 SE 0.000046 p<0.0001 in 
children with multiple autoantibodies, 0.000188 SE 0.000101 p=0.063 in children with 
single autoantibody and 0.000195 SE 0.000060 p=0.0013 in children with no 
autoantibodies. Figure from Koskinen et al., 2018, used under the Creative Commons 
CC by 4.0 licence.  
We compared children who had one biochemical autoantibody at the baseline and 
additional biochemical autoantibodies after or before the first IVGTT. The median 
of the first FPIR in children with one biochemical autoantibody at the baseline and 
an additional biochemical autoantibody after the first IVGTT was 85.0 mU/l (95% 
CI 52.1 mU/l-110.2 mU/l). In children with one biochemical autoantibody at the 
baseline and the second biochemical autoantibody before the first IVGTT the median 
of the first FPIR was 50.3 mU/l (95% CI 32.6 mU/l-89.8 mU/l). The difference 
between the groups did not reach significance (p=0.16, unpublished result).  
We found that there is an association between decreased FPIR and multiple 
autoantibodies. The presence of multiple autoantibodies multiplies the risk of T1D 
(Ziegler et al., 2013). The presence of two autoantibodies with dysglycemia marks a 
different stage in the process of T1D development (Insel et al., 2015). The decreasing 
capacity to secrete insulin was also associated with multiple autoantibodies 
independent of the class II HLA risk group indicating that presence of multiple 
autoantibodies may be secondary to the initial beta cell injury.  
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The increase in FPIR over time was seen also in children with no biochemical 
autoantibodies. This is similar to the findings in the study I where an increase in FPIR 
over time was seen in children with ICA only. However, study II reports a new 
observation that also children with one biochemical autoantibody had increasing 
FPIR over time. Furthermore, difference between FPIR in children with 0 or 1 
biochemical autoantibody was not statistically significant (p=0.3). 
Overall, the beta cell failure was associated with the presence of multiple 
autoantibodies. The declining pattern in FPIR was associated with multiple 
autoantibodies irrespective of HLA risk group. This result was corroborated by our 
finding that the difference between the last and the baseline FPIR per time in years 
(∆FPIR) was significant in all groups of children with multiple autoantibodies 
regardless of the HLA risk group, indicating the possible role of other genetic factors 
than class II HLA in the longitudinal pattern of FPIR. In the following analyses we 
searched for the associations between FPIR and specific genetic variants outside 
class II HLA region.  
5.3 Associations of FPIR and genetic variants 
outside class II HLA region (study III) 
In study III, we investigated whether genetic variants outside the class II region 
associate with the change of FPIR over time. Children had been categorised 
according to the presence of multiple biochemical islet autoantibodies.  
In children with multiple autoantibodies, the change of FPIR over time was 
significantly different between subjects with various PTPN2 (rs45450798), FUT2 
(rs601338), CTSH (rs3825932) and IKZF4 (rs1701704) genotypes in at least one of 
the analytical models. In general, children carrying susceptibility alleles for T1D had 
steeper decline of FPIR compared to children without susceptibility alleles. The 
presence of the class I HLA A*24 allele was also associated with steeper decline of 
FPIR over time in children with multiple autoantibodies. 
Thus, a more rapid decline in insulin secretion was observed in children carrying 
susceptibility alleles in these genes compared to children without susceptibility 
alleles. CTSH has been linked with beta cell function (Fløyel et al., 2014). PTPN2 
has been shown to take part in the beta cell apoptosis (Moore et al., 2009).The effect 
of class I HLA A*24 allele on the development of T1D was observed in a previous 
study analyzing Finnish subjects, although the effect was restricted to  specific HLA-
DR/DQ haplotypes (Mikk et al., 2017). 
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5.4 Other markers of glucose metabolism (study I)  
In study I we investigated also other markers of glucose metabolism from the onset 
of islet autoimmunity. Overall, the findings using the area under the 10-minute 
insulin curve (AUC0-10 min for insulin) were similar to the results of FPIR. The change 
in AUC0-10 min for insulin in the last two samples before diagnosis was significant 
(p<0.0005) and compared to non-progressors AUC0-10 min for insulin was also 
decreased up to the time of 4-6 years before the diagnosis (p<0.005). In the age 
dependent comparison, there was a difference in AUC0-10 min for insulin between the 
groups (p<0.001), the difference between the groups was increased slightly more 
over time compared to FPIR: at 2 years the estimate for the difference was 36% (95% 
CI 17%-58%) and at 10 years the difference was 186% (95% CI 143%-237%). Thus, 
according to these results, FPIR and the area under the 10-minute curve are similar 
markers of beta cell function. FPIR is a good marker for the initial 10-minute insulin 
response, although it can slightly underestimate the difference compared to AUC0-10 
min for insulin curve. 
Before diagnosis, the change of fasting insulin did not reach significance when 
the last two time points were analyzed (p=0.07). The change of fasting glucose, 
HOMA-IR and HOMA-IR to FPIR -ratio in the last two time points before diagnosis 
were significant (p<0.005 for all). HOMA to FPIR -ratio was increased in the 
progressors up to the time of 4-6 years before the diagnosis and fasting glucose was 
increased during 0-2 years prior to diagnosis (p<0.01 for both). HOMA-IR or fasting 
insulin did not differ between the groups before diagnosis. Occasionally HOMA to 
FPIR -ratio has been used as a marker of insulin resistance in the prediction of T1D 
(Fourlanos et al., 2004), but it should be acknowledged that the low FPIR 
significantly contributes to this value. 
In the whole study cohort of study I, fasting insulin, fasting glucose and HOMA-
IR increased over time in both groups: fasting insulin increased 3.9% (95% CI 2.5%-
5.2%) per year, fasting glucose 0.50% (95% CI 0.17%-0.83%) per year and HOMA-
IR index increased 4.4% (95% CI 2.9%-5.9%) per year (p<0.005).When glucose at 
60 minutes during the IVGTT was analyzed separately from the Turku cohort, the 
change in glucose at 60 minutes was significant in the last two samples before 
diagnosis (p<0.001). Glucose at 60 minutes was increased in the progressors 0-2 
years and 2-4 years before the diagnosis (p<0.001, p=0.03, respectively). Glucose at 
60 minutes was higher in the progressors from the age of 6 years onwards (p<0.001) 
and the difference increased with age: at 6 years the difference was 11% (95% CI 
7%-15%) and at 10 years the difference was 24% (95% CI 18%-29%).  
Taken together, a deterioration of glucose tolerance can be observed over time 
in the cohort of DIPP children with any islet autoantibodies, including ICA only. 
Indeed, this is known to occur with age also in healthy individuals (Ferrannini et al., 
2010). In the DIPP study a rise in HOMA and its components fasting insulin and 
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fasting glucose was observed over time in both non-progressors and progressors. The 
fasting glucose may show more rapid increase before diagnosis after earlier linear 
increase (Ferrannini et al., 2010). In the DIPP study we could not observe differences 
in glucose metabolism based on the initiating autoantibody in the time period of 2 
±1 year prior to diagnosis, but this also could be due to the relatively low number 
within the subgroups.  
5.5 General discussion 
Our main finding of this study was that FPIR, a measure of beta cell function that 
represents the release of insulin granules located in the proximity of beta cell 
membrane, is decreased several years before diagnosis of T1D. When compared to 
non-progressors, we could observe a difference in the beta cell secretory capacity of 
progressor children 4-6 years prior to diagnosis of T1D. In the age dependent 
comparison, progressors had constantly lower insulin secretory capacity throughout 
the whole childhood and the difference was observed already at the age of 2 years. 
In addition, we found that the declining pattern of FPIR was associated with multiple 
biochemical islet autoantibodies.  
In the age dependent comparison, the difference between the groups increased 
over time: mean FPIR values were almost three times greater in the non-progressors 
at the age of 10 years compared to progressors. The difference between the groups 
was mostly due to the growth of FPIR over time in non-progressors, which did not 
occur in progressors. Although there was an overall declining pattern of FPIR before 
T1D diagnosis, the fastest decline appears to occur approximately one year before 
disease onset. The pattern of FPIR in the progressors can potentially be more stable 
or even have periods of recovery over time (Srikanta et al, 1984). 
In very young (mean age 2.5 years) DIPP study children most (11 out of 13) of 
the progressors had a FPIR below the fifth percentile already in the first test 
(Keskinen et al., 2001). Still, 11 out of 22 with low values did not progress to T1D 
during the study follow-up. Some of the study children had a second IVGTT and in 
most cases FPIR was clearly higher in the second test when the first test resulted 
over the fifth percentile, suggesting the importance of beta cell function growth 
during the first years of life. 
Beta cell dysfunction, defined as differences in C-peptide levels in OGTT, has 
been observed in the DPT-1 study already at the study baseline over five years before 
clinical onset of T1D and a faster change in C-peptide levels occurred 2 years prior 
to the disease onset (Evans-Molina et al., 2018). In a former small study postprandial 
C-peptide was low up to 74 months prior to the onset of T1D (Ginsberg-Fellner et 
al., 1982). It was also noted that once C-peptide levels fell 2 SD below normal, they  
never returned to the normal range (Ginsberg-Fellner et al., 1982). In contrast, 
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among 15 ICA-positive non-progressors who were twins of T1D patients were 
followed for 17 years by IVGTTs, natural fluctuation of FPIR was observed, yet 
none of them ever had a FPIR ever below the first percentile (Srikanta et al., 1984).  
Even with low insulin secretory capacity, there are children who do not progress 
to T1D for a considerably long time. The DIPP study investigated children with at 
least one islet biochemical autoantibody, 151 of them defined as progressors during 
the study follow-up, and found that a reduced FPIR <24 mU/l was clearly associated 
with T1D risk (5-year progression rate over 80%) (Siljander et al., 2013). Children 
with FPIR <59 mU/l remained healthy much longer (5-year progression rate 21%) 
(Siljander et al., 2013). Among DPT-1 participants (median age of 11 years at 
randomization for oral insulin and 12 years for parenteral insulin) there were subjects 
that were initially classified at having a low FPIR value at the time of the initial test 
but remained healthy during the next 5-6 years (Barker et al., 2007). In 12 identical 
twins of T1D patients that developed diabetes after a mean follow up of 3 years, the 
initial sample of FPIR was already significantly lower in preclinical twins compared 
to control children (Hawa et al., 2005). In twins of T1D patients that had not 
developed T1D, there was no significant difference to control subjects although 
FPIR values were more stable (mean values of 465 mIU/ml-1·10 min-1 and 499 
mIU/ml-1·10 min-1 in low risk twins against 796 mU/ml-1·10min-1 and 433 mIU/ml-
1·10 min-1 in controls) (Hawa et al., 2005).  
Although in children progressing to T1D the insulin secretory capacity was 
significantly lower throughout the childhood than in those who did not progress to 
T1D a difference in 60-minute glucose values was significant from the age of 6 years 
onwards and from the time period of 2 to 4 years prior to diagnosis, implying that 
subjects progressing to T1D somehow adapt or compensate for the low insulin 
secretory capacity before the rise in glucose values is observable. In the DIPP study 
it was observed that 2-hour OGTT plasma glucose starts to rise approximately 2 
years before diagnosis and a random plasma glucose value of over 7.8 mmol/l was 
very predictive of future T1D (Helminen et al., 2015). Changes in Hba1c preceded 
T1D diagnosis approximately 2 years (Helminen et al., 2015). When compared to 
autoantibody negative controls DIPP study children with multiple autoantibodies 
had delicate signs of change in glucose metabolism, such as a higher variation in 
glucose levels and increased evening glucose values (Helminen et al., 2016).  
In this study we observed an increase over time in markers of insulin resistance 
in both non-progressors and progressors. Glucose tolerance is known to deteriorate 
over time even in healthy subjects (Ferrannini et al., 2011). As there is an overall 
increase in insulin resistance over time, and occasional periods of increased insulin 
resistance, children who progress to T1D may at that time fail to increase beta cell 
function enough to maintain glucose homeostasis. Fluctuations between 
dysglycemia and normoglycemia have been observed before T1D during a long 
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follow-up (Sosenko et al., 2009). However, the manner in which normoglycemia is 
achieved in these subjects remains unknown.  
The correlation between FPIR and pancreatic insulin content in baboons has been 
described as strong and crossing the y-axis at zero (McCulloch et al., 1991). 
However, the correlation between  FPIR and beta cell mass has been shown to 
intercept the y-axis at 0.19 g suggesting there would be histologically detectable beta 
cells even when insulin response approaches zero (McCulloch et al., 1991). This is 
in line with the many observations that beta cells are still present in T1D patients 
(Gepts & De Mey, 1978; Maclean & Ogilvie, 1959). Some insulin secretion has been 
shown to exist years after T1D diagnosis (Keenan et al., 2010; Oram et al., 2014). 
The remaining insulin secretion could be a result of persisting beta cells (Lam et al., 
2017). When subjects with insulitis or autoantibody positivity were investigated, a 
decrease in beta cell mass was not observed, and moreover, in some of the islets 
there were signs of beta cell proliferation (In't Veld et al., 2007). Surprisingly, when 
beta cell mass was estimated by the proinsulin area the organ donors with islet 
autoantibodies had larger beta cell mass compared to control donors (Rodriguez-
Calvo et al., 2017).  
Overall, factors that could contribute to low insulin secretory capacity include 
viruses (Henderson et al., 1991; Naghavi & Walsh, 2017), free fatty acids (Kashyap 
et al., 2003; Paolisso et al., 1995), metals and  pollutants (Alonso-Magdalena et al., 
2010; Diaz-Villasenor et al., 2006; Henriksen et al., 1997; Lee et al., 2017). In mice, 
the postnatal maternal diet was not linked to beta cell mass in offspring, but glucose 
intolerance was observed with dysfunction of the hypothalamic neurocircuitry (Vogt 
et al., 2014). The prenatal maternal high fat diet in rodents has also been associated 
with insulin values of the offspring; insulin levels were low at birth and 
hyperinsulinemia was present in adult age (Howie et al., 2009). 
The class II HLA  genotypes that are mostly known to be associated with a T1D 
risk exert their effect in the development of islet autoimmunity. The time between 
the development of autoimmunity and the onset of T1D can range from weeks to 
decades. In the DIPP study the median time from the appearance of islet 
autoantibodies to T1D was 2.5 years with a maximum period of 12 years (Parikka et 
al., 2012), while in Finnish subjects recruited from the general population this period 
reached 20 years (Knip et al., 2010). In the DIPP study the decreasing capacity of 
insulin secretion was associated with multiple biochemical autoantibodies regardless 
of the class II HLA risk group. HLA-independent associations have also been 
observed in siblings of patients with T1D when fasting proinsulin values were 
described to be higher than in control subjects (Hartling et al., 1989; Lindgren et al., 
1991). With decreased level of immediately available insulin, this could increase 
beta cell stress. Years before insulin treatment was needed, the insulin response to 
oral glucose was reported to be above normal (Ilonen et al., 1980).  
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The class II HLA risk genotypes may also be associated with more high-affinity 
immunity and maturation of the permanent autoantibody response (Gullstrand et al., 
2008). In mice, B cells produced autoantibodies that activated T cells, and this was 
shown to promote glucose intolerance (Winer et al., 2011). Presence of islet 
autoantibodies also predicted worsening of beta cell function in T2D patients (Turner 
et al., 1997). LADA patients have shared genes in common with T1D but also with 
T2D patients (Cousminer et al., 2018).  
As the decreased capacity to secrete insulin was not independently associated 
with the class II HLA risk genotype it is still possible that other genetic factors can 
potentially influence the longitudinal pattern of FPIR. Indeed, the results of study III 
showed that certain genetic variants outside the class II HLA region can affect the 
longitudinal pattern of insulin response. The presence of the class I A*24 allele was 
associated with steeper decline in insulin secretion in the current study and also the 
rate of progression to T1D in an earlier analysis (Mikk et al., 2017). Beta cells can 
express autoantigens in the context of class I HLA molecule (Richardson et al., 
2016). 
The CTSH CC genotype was associated with a faster decline in insulin secretion 
in children with multiple autoantibodies when compared with other genotypes. 
Interestingly, in an earlier study, the CTSH CC genotype has been associated with 
CTSH overexpression which increased chronic insulin release and decreased 
cytokine-induced apoptosis (Fløyel et al., 2014). The proinflammatory cytokines 
were shown to decrease the CTSH expression in human islets (Fløyel et al., 2014).  
PTPN2 can sensitize beta cells to surrounding proapoptotic cytokines especially 
in the vicinity of local inflammation (Santin et al., 2011). Treg cells that were 
reprogrammed by the transcription factor Eos have been shown to respond rapidly 
to the inflammation site (Sharma et al., 2013). The finding that FUT2 was associated 
with a change in insulin secretory capacity was surprising. Still, the secretor status 
has been associated with intestinal microbiota composition (Kumar et al., 2015; 
Wacklin et al., 2011) and there are associations between autoimmunity and the 
microbiome (Davis-Richardson et al., 2014; Vatanen et al., 2016). The growth and 
development of beta cells is likely to be optimal in the presence of healthy 
microbiome. 
Compared to other stimuli, the beta cell insensitivity to glucose has been shown 
to be more severe in early T1D or in remission without insulin treatment (Ganda et 
al., 1984). A defect in beta cell glucose recognition has been estimated to be present 
years before diagnosis (Ferrannini et al., 2010). The impaired glucose sensing of the 
beta cell instead of a defect in the compensation for insulin resistance has been 
suggested to be the key determinant in glucose intolerance (Mari et al., 2011). 
Dysregulation of insulin response is known to occur when glucose levels are above 
normal (Brunzell et al., 1976). The increase in metabolic flux can lead to chronic 
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beta cell stress and potentially irreversible dysfunction of the cell (Eizirik et al., 
2008; Robertson et al., 2003). This is accompanied by the accumulation of unfolded 
proteins and diminished activity of insulin gene activator (Eizirik et al., 2008; Poitout 
et al., 1996). 
The strength of this study is that it includes data about young children 
representing a population that has the highest global incidence of T1D. The long 
follow-up and repeated monitoring of autoantibodies and IVGTTs in a large cohort 
of children who were observed from birth has built a  unique dataset for this study. 
However, our study subjects were young children and results may not be 
generalizable to adults. The protective genotypes are common in the general 
population but were present in a minority of subjects in our study.  
In children progressing to T1D the capacity to secrete insulin is impaired several 
years before the onset of T1D. The impairment of the beta cells can be due to extra 
burden or specific environmental factors. The failure to increase the insulin secretory 
capacity over time implies that there can be problems in the development of beta cell 
mass or function. If we were able to pinpoint the specific defect or learn the 
compensatory mechanisms that delay the disease onset despite of the low insulin 
secretion capacity we might find opportunities to prevent the development of T1D.  
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6 Conclusions 
The main conclusions of this thesis include: 
1. FPIR is decreased 4–6 years before the onset of T1D in children that 
progressed to T1D (progressors) compared to children who did not progress 
to T1D during the follow-up (non-progressors). 
2. Progressors  have significantly lower mean FPIR values throughout  childhood 
compared to non-progressors and the difference between the groups increases 
with age.  
3. The association between the class II HLA T1D risk group and FPIR is 
explained by the appearance of islet autoantibodies. The declining FPIR is 
associated with multiple autoantibodies irrespective of the class II HLA risk.  
4. The longitudinal pattern of FPIR values may be modified by genetic variants 
outside the class II HLA region. 
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